efficacy balance of formulation(s) of the active ingredient, and assessing its overall and relative therapeutic value. The pattern and profile of any frequent adverse reactions must be investigated, and special features of the product must be explored (e.g. clinically relevant drug interactions, factors leading to differences in effect, such as age). The trials should preferably be randomized double-blind, but other designs may be acceptable, e.g. long-term safety studies. In general, the conditions under which the trials are conducted should be as close as possible to the normal conditions of use.

**Phase IV** In this phase studies are performed after the pharmaceutical product has been marketed. They are based on the product characteristics on which the marketing authorization was granted and normally take the form of post-marketing surveillance, and assessment of therapeutic value or treatment strategies. Although methods may differ, the same scientific and ethical standards should apply to Phase IV studies as are applied in premarketing studies. After a product has been placed on the market, clinical trials designed to explore new indications, new methods of administration or new combinations, etc., are normally regarded as trials of new pharmaceutical products.

**Investigational product**  
Any pharmaceutical product (new product or reference product) or placebo being tested or used as a reference in a clinical trial.

**Investigator**  
The person responsible for the trial and for protecting the rights, health and welfare of the subjects in the trial. The investigator must be an appropriately qualified person legally allowed to practise medicine/dentistry.

**Monitor**  
A person appointed by, and responsible to, the sponsor for monitoring and reporting the progress of the trial and for the verification of data.

**Order**  
An instruction to process, package and/or ship a certain number of units of an investigational product.

**Pharmaceutical product**  
For the purpose of this Annex, this term is defined in the same way as in the WHO guidelines on GCP (3), i.e. as any substance or combination of substances which has a therapeutic, prophylactic or diagnostic purpose, or is intended to modify physiological functions, and is presented in a dosage form suitable for administration to humans.

**Product specification file(s)**  
Reference file(s) containing all the information necessary to draft the detailed written instructions on processing, packaging, labelling, quality control testing, batch release, storage conditions and shipping.
**protocol**
A document which gives the background, rationale and objectives of the trial and describes its design, methodology and organization, including statistical considerations, and the conditions under which it is to be performed and managed. It should be dated and signed by the investigator/institution involved and the sponsor, and can, in addition, function as a contract.

**shipping/dispatch**
The assembly, packing for shipment, and sending of ordered medicinal products for clinical trials.

**sponsor**
An individual, company, institution or organization which takes responsibility for the initiation, management and/or financing of a clinical trial. When an investigator independently initiates and takes full responsibility for a trial, the investigator then also assumes the role of the sponsor.

4. **Quality assurance**
Quality assurance of pharmaceutical products has been defined and discussed in detail in the guide on GMP (2, pages 25-26).

The quality of dosage forms in Phase III clinical studies should be characterized and assured at the same level as for routinely manufactured products. The quality assurance system, designed, established and verified by the manufacturer, should be described in writing, taking into account the GMP principles to the extent that they are applicable to the operations in question. This system should also cover the interface between the manufacture and the trial site (e.g. shipment, storage, occasional additional labelling).

5. **Validation**
Some of the production processes for investigational products that have not received marketing authorization may not be validated to the extent necessary for a routine production operation. The product specifications and manufacturing instructions may vary during development. This increased complexity in the manufacturing operations requires a highly effective quality assurance system.

For sterile products, there should be no reduction in the degree of validation of sterilizing equipment required. Validation of aseptic processes presents special problems when the batch size is small, since the number of units filled may be not adequate for a validation exercise. Filling and sealing, which is often done by hand, can compromise the

---

1 For additional advice on validation, see Annex 6.
maintenance of sterility. Greater attention should therefore be given to environmental monitoring.

6. **Complaints**

   The conclusions of any investigation carried out in response to a complaint should be discussed between the manufacturer and the sponsor (if different) or between the persons responsible for manufacture and those responsible for the relevant clinical trial in order to assess any potential impact on the trial and on the product development, to determine the cause, and to take any necessary corrective action.

7. **Recalls**

   Recall procedures should be understood by the sponsor, investigator and monitor in addition to the person(s) responsible for recalls, as described in the guide on GMP (2, pages 28-29).

8. **Personnel**

   Although it is likely that the number of staff involved will be small, people should be separately designated as responsible for production and quality control. All production operations should be carried out under the control of a clearly identified responsible person. Personnel concerned with development, involved in production and quality control, need to be instructed in the principles of GMP.

9. **Premises and equipment**

   During the manufacture of investigational products, different products may be handled in the same premises and at the same time, and this reinforces the need to eliminate all risks of contamination, including cross-contamination. Special attention should be paid to line clearance in order to avoid mix-ups. Validated cleaning procedures should be followed to prevent cross-contamination.

   For the production of the particular products referred to in section 11.20 of the guide on GMP (2, page 38), campaign working may be acceptable in place of dedicated and self-contained facilities. Because the toxicity of the materials may not be fully known, cleaning is of particular importance; account should be taken of the solubility of the product and excipients in various cleaning agents.

10. **Materials**

    **Starting materials**

    The consistency of production may be influenced by the quality of the starting materials. Their physical, chemical and, when appropriate,
microbiological properties should therefore be defined, documented in their specifications, and controlled. Existing compendial standards, when available, should be taken into consideration. Specifications for active ingredients should be as comprehensive as possible, given the current state of knowledge. Specifications for both active and non-active ingredients should be periodically reassessed.

Detailed information on the quality of active and non-active ingredients, as well as of packaging materials, should be available so as to make it possible to recognize and, as necessary, allow for any variation in production.

**Chemical and biological reference standards for analytical purposes**

Reference standards from reputable sources (WHO or national standards) should be used, if available; otherwise the reference substance(s) for the active ingredient(s) should be prepared, tested and released as reference material(s) by the producer of the investigational pharmaceutical product, or by the producer of the active ingredient(s) used in the manufacture of that product.

**Principles applicable to reference products for clinical trials**

In studies in which an investigational product is compared with a marketed product, steps should be taken to ensure the integrity and quality of the reference products (final dosage form, packaging materials, storage conditions, etc.). If significant changes are to be made in the product, data should be available (e.g. on stability, comparative dissolution) that demonstrate that these changes do not influence the original quality characteristics of the product.

11. **Documentation**

Specifications (for starting materials, primary packaging materials, intermediate and bulk products and finished products), master formulae, and processing and packaging instructions may be changed frequently as a result of new experience in the development of an investigational product. Each new version should take into account the latest data and include a reference to the previous version so that traceability is ensured. Rationales for changes should be stated and recorded.

Batch processing and packaging records should be retained for at least 2 years after the termination or discontinuance of the clinical trial, or after the approval of the investigational product.

**Order**

The order may request the processing and/or packaging of a certain number of units and/or their shipping. It may only be given by the sponsor to the manufacturer of an investigational product. It should be in
writing (though it may be transmitted by electronic means), precise enough to avoid any ambiguity and formally authorized, and refer to the approved product specification file (see below).

**Product specification file(s)**

A product specification file (or files) should contain the information necessary to draft the detailed written instructions on processing, packaging, quality control testing, batch release, storage conditions and/or shipping. It should indicate who has been designated or trained as the authorized person responsible for the release of batches (see reference 2, page 18). It should be continuously updated while at the same time ensuring appropriate traceability to the previous versions.

**Specifications**

In developing specifications, special attention should be paid to characteristics which affect the efficacy and safety of pharmaceutical products, namely:

- The accuracy of the therapeutic or unitary dose: homogeneity, content uniformity.
- The release of active ingredients from the dosage form: dissolution time, etc.
- The estimated stability, if necessary, under accelerated conditions, the preliminary storage conditions and the shelf-life of the product.¹

In addition, the package size should be suitable for the requirements of the trial.

Specifications may be subject to change as the development of the product progresses. Changes should, however, be made in accordance with a written procedure authorized by a responsible person and clearly recorded. Specifications should be based on all available scientific data, current state-of-the-art technology, and the regulatory and pharmacopoeial requirements.

**Master formulae and processing instructions**

These may be changed in the light of experience, but allowance must be made for any possible repercussions on stability and, above all, on bioequivalence between batches of finished products. Changes should be made in accordance with a written procedure, authorized by a responsible person and clearly recorded.

It may sometimes not be necessary to produce master formulae and processing instructions, but for every manufacturing operation or supply there should be clear and adequate written instructions and written records. Records are particularly important for the preparation of the final version of the documents to be used in routine manufacture.

¹ See Annex 5.
Packaging instructions

The number of units to be packaged should be specified before the start of the packaging operations. Account should be taken of the number of units necessary for carrying out quality controls and of the number of samples from each batch used in the clinical trial to be kept as a reference for further rechecking and control. A reconciliation should be carried out at the end of the packaging and labelling process.

Labelling instructions

The information presented on labels should include:

- The name of the sponsor.
- A statement: “for clinical research use only”.
- A trial reference number.
- A batch number.
- The patient identification number.¹
- The storage conditions.
- The expiry date (month/year) or a retest date.

Additional information may be displayed in accordance with the order (e.g. dosing instructions, treatment period, standard warnings). When necessary for blinding purposes, the batch number may be provided separately (see also “Blinding operations” on p. 106). A copy of each type of label should be kept in the batch packaging record.

Processing and packaging batch records

Processing and packaging batch records should be kept in sufficient detail for the sequence of operations to be accurately traced. They should contain any relevant remarks which increase existing knowledge of the product, allow improvements in the manufacturing operations, and justify the procedures used.

Coding (or randomization) systems

Procedures should be established for the generation, distribution, handling and retention of any randomization code used in packaging investigational products.

A coding system should be introduced to permit the proper identification of "blinded" products. The code, together with the randomization list, must permit proper identification of the product, including any necessary traceability to the codes and batch number of the product before the blinding operation. The coding system must permit determination without delay in an emergency situation of the identity of the actual treatment product received by individual subjects.

¹ This is not necessarily inserted at the manufacturing facility but may be added at a later stage.
12. Production

Products intended for use in clinical trials (late Phase II and Phase III studies) should as far as possible be manufactured at a licensed facility, e.g.:

- A pilot plant, primarily designed and used for process development.
- A small-scale facility (sometimes called a “pharmacy”)\(^1\) separate both from the company’s pilot plant and from routine production.
- A larger-scale production line assembled to manufacture materials in larger batches, e.g. for late Phase III trials and first commercial batches.
- The normal production line used for licensed commercial batches, and sometimes for the production of investigational pharmaceutical products if the number, e.g. of ordered ampoules, tablets or other dosage forms, is large enough.

The relation between the batch size for investigational pharmaceutical products manufactured in a pilot plant or small-scale facility to the planned full-size batches may vary widely depending on the pilot plant or “pharmacy” batch size demanded and the capacity available in full-size production.

The present guidelines are applicable to licensed facilities of the first and second types. It is easier to assure compliance with GMP in facilities of the second type, since processes are kept constant in the course of production and are not normally changed for the purpose of process development. Facilities of the remaining types should be subject to all GMP rules for pharmaceutical products.

Administratively, the manufacturer has yet another possibility, namely to contract out the preparation of investigational products. Technically, however, the licensed facility will be of one of the above-mentioned types. The contract must then clearly state, inter alia, the use of the pharmaceutical product(s) in clinical trials. Close cooperation between the contracting parties is essential.

Manufacturing operations

Validated procedures may not always be available during the development phase, which makes it difficult to know in advance what critical parameters and in-process controls would help to control these parameters. Provisional production parameters and in-process controls may then usually be deduced from experience with analogous products. Careful consideration by key personnel is called for in order to formulate the necessary instructions and to adapt them continuously to the experience gained in production.

\(^1\) Some manufacturers use the term “pharmacy” to designate other types of premises, e.g. areas where starting materials are dispensed and batches compounded.
For sterile investigational products, assurance of sterility should be no less than for licensed products. Cleaning procedures should be appropriately validated and designed in the light of the incomplete knowledge of the toxicity of the investigational product. Where processes such as mixing have not been validated, additional quality control testing may be necessary.

Packaging and labelling

The packaging and labelling of investigational products are likely to be more complex and more liable to errors (which are also harder to detect) when “blinded” labels are used than for licensed products. Supervisory procedures such as label reconciliation, line clearance, etc., and the independent checks by quality control staff should accordingly be intensified.

The packaging must ensure that the investigational product remains in good condition during transport and storage at intermediate destinations. Any opening of, or tampering with, the outer packaging during transport should be readily discernible.

Blinding operations

In the preparation of “blinded” products, in-process control should include a check on the similarity in appearance and any other required characteristics of the different products being compared.

13. Quality control

As processes may not be standardized or fully validated, end-product testing is more important in ensuring that each batch meets its specification.

Product release is often carried out in two stages, before and after final packaging:

1. Bulk product assessment: this should cover all relevant factors, including production conditions, the results of in-process testing, a review of manufacturing documentation and compliance with the product specification file and the order.

2. Finished product assessment: this should cover, in addition to the bulk product assessment, all relevant factors, including packaging conditions, the results of in-process testing, a review of packaging documentation and compliance with the product specification file and the order.

When necessary, quality control should also be used to verify the similarity in appearance and other physical characteristics, odour, and taste of “blinded” investigational products.

---

1 This practice also exists at certain large companies with regard to licensed products.
Samples of each batch of product should be retained in the primary container used for the study or in a suitable bulk container for at least 2 years after the termination or completion of the relevant clinical trial. If the sample is not stored in the pack used for the study, stability data should be available to justify the shelf-life in the pack used.

14. **Shipping, returns, and destruction**

The shipping, return and destruction of unused products should be carried out in accordance with the written procedures laid down in the protocol. All unused products sent outside the manufacturing plant should, as far as possible, either be returned to the manufacturer or destroyed in accordance with clearly defined instructions.

**Shipping**

Investigational products should be shipped in accordance with the orders given by the sponsor.

A shipment is sent to an investigator only after the following two-step release procedure: (i) the release of the product after quality control ("technical green light"); and (ii) the authorization to use the product, given by the sponsor ("regulatory green light"). Both releases should be recorded.

The sponsor should ensure that the shipment will be received and acknowledged by the correct addressee as stated in the protocol.

A detailed inventory of the shipments made by the manufacturer should be maintained, and should make particular mention of the addressee’s identification.

**Returns**

Investigational products should be returned under agreed conditions defined by the sponsor, specified in written procedures, and approved by authorized staff members.

Returned investigational products should be clearly identified and stored in a dedicated area. Inventory records of returned medicinal products should be kept. The responsibilities of the investigator and the sponsor are dealt with in greater detail in the WHO guidelines on GCP (3).

**Destruction**

The sponsor is responsible for the destruction of unused investigational products, which should therefore not be destroyed by the manufacturer without prior authorization by the sponsor. Destruction operations should be carried out in accordance with environmental safety requirements.

Destruction operations should be recorded in such a manner that all operations are documented. The records should be kept by the sponsor.
If requested to destroy products, the manufacturer should deliver a certificate of destruction or a receipt for destruction to the sponsor. These documents should permit the batches involved to be clearly identified.

References


Annex 8

Good manufacturing practices: supplementary guidelines for the manufacture of herbal medicinal products

1. Glossary

The definitions given below apply to the terms used in these guidelines. They may have different meanings in other contexts.

constituents with known therapeutic activity
Substances or groups of substances which are chemically defined and known to contribute to the therapeutic activity of a plant material or of a preparation.

herbal medicinal product
Medicinal product containing, as active ingredients, exclusively plant material and/or preparations. This term is generally applied to a finished product. If it refers to an unfinished product, this should be indicated.

markers
 Constituents of a medicinal plant material which are chemically defined and of interest for control purposes. Markers are generally employed when constituents of known therapeutic activity are not found or are uncertain, and may be used to calculate the quantity of plant material or preparation in the finished product. When starting materials are tested, markers in the plant material or preparation must be determined quantitatively.

medicinal plant
A plant (wild or cultivated) used for medicinal purposes.

medicinal plant material (crude plant material, vegetable drug)
Medicinal plants or parts thereof collected for medicinal purposes.

plant preparations
Comminuted or powdered plant material, extracts, tinctures, fatty or essential oils, resins, gums, balsams, expressed juices, etc., prepared from plant material, and preparations whose production involves a fractionation, purification or concentration process, but excluding chemically defined isolated constituents. A plant preparation can be regarded as the active ingredient whether or not the constituents having therapeutic activities are known.

---

1 Guidelines for the assessment of herbal medicines are provided in Annex 11.
2. General

Unlike conventional pharmaceutical products, which are usually prepared from synthetic materials by means of reproducible manufacturing techniques and procedures, herbal medicinal products are prepared from material of plant origin which may be subject to contamination and deterioration, and may vary in composition and properties. Furthermore, in the manufacture and quality control of herbal medicinal products, procedures and techniques are often used which are substantially different from those employed for conventional pharmaceutical products.

The control of the starting materials, storage and processing assumes particular importance because of the often complex and variable nature of many herbal medicinal products and the number and the small quantity of defined active ingredients present in them.

3. Premises

Storage areas

Medicinal plant materials should be stored in separate areas. The storage area should be well ventilated and equipped in such a way as to protect against the entry of insects or other animals, especially rodents. Effective measures should be taken to limit the spread of animals and microorganisms introduced with the plant material and to prevent cross-contamination. Containers should be located in such a way as to allow free air circulation.

Special attention should be paid to the cleanliness and good maintenance of the storage areas, particularly when dust is generated.

The storage of plants, extracts, tinctures and other preparations may require special conditions of humidity and temperature or protection from light; steps should be taken to ensure that these conditions are provided and monitored.

Production area

To facilitate cleaning and to avoid cross-contamination whenever dust is generated, special precautions should be taken during the sampling, weighing, mixing and processing of medicinal plants, e.g. by the use of dust extraction or dedicated premises.

4. Documentation

Specifications for starting materials

In addition to the data called for in sections 14 and 18 of “Good manufacturing practices for pharmaceutical products”(J), the specifications for medicinal plant materials should as far as possible include the following:
• The botanical name, with reference to the authors.
• Details of the source of the plant (country or region of origin, and where applicable, method of cultivation, time of harvesting, collection procedures, possible pesticides used, etc.).
• Whether the whole plant or only a part is used.
• When dried plant is purchased, the drying system.
• A description of the plant material based on visual and/or microscopical inspection.
• Suitable identification tests including, where appropriate, identification tests for known active ingredients or markers.
• The assay, where appropriate, of constituents of known therapeutic activity or markers.
• Suitable methods for the determination of possible pesticide contamination and the acceptable limits for such contamination.
• The results of tests for toxic metals and for likely contaminants, foreign materials and adulterants.
• The results of tests for microbial contamination and aflatoxins.

Any treatment used to reduce fungal/microbial contamination or other infestation should be documented. Instructions on the conduct of such procedures should be available and should include details of the process, tests and limits for residues.

**Qualitative and quantitative requirements**

These should be expressed in the following ways:

1. Medicinal plant material:
   
   (a) the quantity of plant material must be stated; or
   
   (b) the quantity of plant material may be given as a range, corresponding to a defined quantity of constituents of known therapeutic activity.

Example:

<table>
<thead>
<tr>
<th>Name of active ingredient</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Senna folium</td>
<td>(a) 900 mg or (b) 830-1000 mg, corresponding to 25 mg of hydroxyanthracene glycosides, calculated as sennoside B</td>
</tr>
</tbody>
</table>

2. Plant preparation:

   (a) the equivalent quantity or the ratio of plant material to plant preparation must be stated (this does not apply to fatty or essential oils); or

   (b) the quantity of the plant preparation may be given as a range, corresponding to a defined quantity of constituents with known therapeutic activity (see example).

The composition of any solvent or solvent mixture used and the physical state of the extract must be indicated.
If any other substance is added during the manufacture of the plant preparation to adjust the level of constituents of known therapeutic activity, or for any other purpose, the added substance(s) must be described as “other ingredients” and the genuine extract as the “active ingredient”.

Example:

<table>
<thead>
<tr>
<th>Name of active ingredient</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sennae folium</td>
<td>(a) 125 mg ethanolic extract (8:1) or 125 mg ethanolic extract, equivalent to 1000 mg of Sennae folium or (b) 100-130 mg ethanolic extract (8:1), corresponding to 25 mg of hydroxyanthracene glycosides, calculated as sennoside B</td>
</tr>
</tbody>
</table>

Other ingredient

Dextrin 20-50 mg

Specifications for the finished product

The control tests for the finished product must be such as to allow the qualitative and quantitative determination of the active ingredients. If the therapeutic activity of constituents is known, this must be specified and determined quantitatively. When this is not feasible, specifications must be based on the determination of markers.

If either the final product or the preparation contains several plant materials and a quantitative determination of each active ingredient is not feasible, the combined content of several active ingredients may be determined. The need for such a procedure must be justified.

Processing instructions

The processing instructions should list the different operations to be performed on the plant material, such as drying, crushing and sifting, and also include the temperatures required in the drying process, and the methods to be used to control fragments or particle size. Instructions on sieving or other methods of removing foreign materials should also be given. Details of any process, such as fumigation, used to reduce microbial contamination, together with methods of determining the extent of such contamination, should also be given.

For the production of plant preparations, the instructions should specify any vehicle or solvent that may be used, the times and temperatures to be observed during extraction, and any concentration methods that may be required.
5. **Quality control**

The personnel of quality control units should have particular expertise in herbal medicinal products to be able to carry out identification tests, and check for adulteration, the presence of fungal growth or infestations, lack of uniformity in a consignment of medicinal plant materials, etc.

Reference samples of plant materials must be available for use in comparative tests, e.g. visual and microscopic examination and chromatography.

**Sampling**

Sampling must be carried out with special care by personnel with the necessary expertise since medicinal plant materials are composed of individual plants or parts of plants and are therefore heterogeneous to some extent.

Further advice on sampling, visual inspection, analytical methods, etc., is given in *Quality control methods for medicinal plant materials* (2).

6. **Stability tests**

It will not be sufficient to determine the stability only of the constituents with known therapeutic activity, since plant materials or plant preparations in their entirety are regarded as the active ingredient. It must also be shown, as far as possible, e.g. by comparisons of chromatograms, that the other substances present are stable and that their content as a proportion of the whole remains constant.

If a herbal medicinal product contains several plant materials or preparations of several plant materials, and it is not feasible to determine the stability of each active ingredient, the stability of the product should be determined by methods such as chromatography, widely used assay methods, and physical and sensory or other appropriate tests.

**References**


Annex 9

Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability

Introduction 115
Glossary 116

Part One. Regulatory assessment of interchangeable multisource pharmaceutical products 118
1. General considerations 118
2. Multisource products and interchangeability 118
3. Technical data for regulatory assessment 119
4. Product information and promotion 120
5. Collaboration between drug regulatory authorities 121
6. Exchange of evaluation reports 121

Part Two: Equivalence studies needed for marketing authorization 121
7. Documentation of equivalence for marketing authorization 121
8. When equivalence studies are not necessary 122
9. When equivalence studies are necessary and types of studies required
   - In vivo studies 123
   - In vitro studies 124

Part Three. Tests for equivalence 124
10. Bioequivalence studies in humans 126
    - Subjects 127
    - Design 128
    - Studies of metabolites 130
    - Measurements of individual isomers for chiral drug substance products 130
    - Validation of analytical procedures 130
    - Reserve samples 130
    - Statistical analysis and acceptance criteria 131
    - Reporting of results 132
11. Pharmacodynamic studies 132
12. Clinical trials 134
13. In vitro dissolution 135

Part Four: In vitro dissolution tests in product development and quality control 135

Part Five. Clinically important variations in bioavailability leading to non-approval of the product 137

Part Six. Studies needed to support new post-marketing manufacturing conditions 137

Part Seven. Choice of reference product 137

Authors 138
References 139
Introduction

Multisource (generic) drug products must satisfy the same standards of quality, efficacy and safety as those applicable to the originator's product. In addition, reasonable assurance must be provided that they are, as intended, clinically interchangeable with nominally equivalent market products.

With some classes of product, obviously including parenteral formulations of highly water-soluble compounds, interchangeability is adequately assured by the implementation of good manufacturing practices (GMP) and evidence of conformity with relevant pharmacopoeial specifications. For other classes of product, including many biologics, such as vaccines, animal sera, products derived from human blood and plasma, and products manufactured by biotechnology, the concept of interchangeability raises complex considerations that are not addressed here, and these products will consequently not be considered. However, for most nominally equivalent pharmaceutical products (including most solid oral dosage forms), a demonstration of therapeutic equivalence can and should be carried out and should be included in the documentation submitted with the application for marketing authorization.

During the International Conference of Drug Regulatory Authorities (ICDRA) held in Ottawa, Canada, in 1991 and again in The Hague, The Netherlands, in 1994, regulatory officials supported the proposal that WHO should develop global standards and requirements for the regulatory assessment, marketing authorization and quality control of interchangeable multisource (generic) pharmaceutical products. On the basis of these suggestions, WHO convened three consultations during 1993 and 1994 in Geneva which led to the formulation of the present guidelines. Participants at the consultations included representatives of drug regulatory authorities, the universities, and the pharmaceutical industry, including the generic industry.

The objective of these guidelines is not only to provide technical guidance to national drug regulatory authorities and to drug manufacturers on how such assurance can be provided, but also to create an awareness that in some instances failure to assure interchangeability can
prejudice the health and safety of patients. This danger has recently been highlighted in a joint statement by the WHO Tuberculosis Programme and the International Union against Tuberculosis and Lung Disease. This states, *inter alia*, that “studies of fixed-dose combinations containing rifampicin have shown that in some of the preparations the rifampicin was poorly absorbed or not absorbed at all”. Fixed-dosage combinations containing rifampicin must therefore be “demonstrably bioavailable”.

Highly developed national drug regulatory authorities now routinely require evidence of bioavailability for a very large majority of solid oral dosage forms, including those contained in the WHO Model List of Essential Drugs. WHO will assist small regulatory authorities, for whom these guidelines are primarily intended, in determining relevant policies and priorities — in relation to both locally manufactured and imported products — by compiling and maintaining a list of preparations that are known to have given rise to incidents indicative of clinical inequivalence. It will also work to promote a technical basis for assuring the interchangeability of multisource products within both an international and a national context by proposing the establishment of international reference materials as comparators for bioequivalence testing.

These guidelines apply to the marketing of pharmaceutical products intended to be therapeutically equivalent and thus interchangeable (generics) but produced by different manufacturers. They should be interpreted and applied without prejudice to the obligations incurred through existing international agreements on trade-related aspects of intellectual property rights (*I*).

**Glossary**

The definitions given below apply specifically to the terms used in this guide. They may have different meanings in other contexts.

**bioavailability**
The rate and extent of availability of an active drug ingredient from a dosage form as determined by its concentration-time curve in the systemic circulation or by its excretion in urine.

**bioequivalence**
Two pharmaceutical products are bioequivalent if they are pharmaceutically equivalent and their bioavailabilities (rate and extent of availability), after administration in the same molar dose, are similar to such a degree that their effects can be expected to be essentially the same.

**dosage form**
The form of the completed pharmaceutical product, e.g. tablet, capsule, elixir, injection, suppository.
therapeutic equivalence
Two pharmaceutical products are therapeutically equivalent if they are pharmaceutically equivalent and after administration in the same molar dose their effects, with respect to both efficacy and safety, will be essentially the same, as determined from appropriate studies (bioequivalence, pharmacodynamic, clinical or in vitro studies).

generic product
The term “generic product” has somewhat different meanings in different jurisdictions. In this document, therefore, use of this term is avoided as much as possible, and the term “multisource pharmaceutical product” (see definition below) is used instead. Generic products may be marketed either under the nonproprietary approved name or under a new brand (proprietary) name. They may sometimes be marketed in dosage forms and/or strengths different from those of the innovator products. However, where the term “generic product” has had to be used in this document, it means a pharmaceutical product, usually intended to be interchangeable with the innovator product, which is usually manufactured without a licence from the innovator company and marketed after the expiry of patent or other exclusivity rights.

innovator pharmaceutical product
Generally, the innovator pharmaceutical product is that which was first authorized for marketing (normally as a patented drug) on the basis of documentation of efficacy, safety and quality (according to contemporary requirements). When drugs have been available for many years, it may not be possible to identify an innovator pharmaceutical product.

interchangeable pharmaceutical product
An interchangeable pharmaceutical product is one which is therapeutically equivalent to a reference product.

multisource pharmaceutical products
Multisource pharmaceutical products are pharmaceutically equivalent products that may or may not be therapeutically equivalent. Multisource pharmaceutical products that are therapeutically equivalent are interchangeable.

pharmaceutical equivalence
Products are pharmaceutical equivalents if they contain the same amount of the same active substance(s) in the same dosage form; if they meet the same or comparable standards; and if they are intended to be administered by the same route. However, pharmaceutical equivalence does not necessarily imply therapeutic equivalence as differences in the excipients and/or the manufacturing process can lead to differences in product performance.
A reference product is a pharmaceutical product with which the new product is intended to be interchangeable in clinical practice. The reference product will normally be the innovator product for which efficacy, safety and quality have been established. Where the innovator product is not available, the product which is the market leader may be used as a reference product, provided that it has been authorized for marketing and its efficacy, safety and quality have been established and documented.

Part One. Regulatory assessment of interchangeable multisource pharmaceutical products

1. General considerations

The national health authorities (national drug regulatory authorities) should ensure that all pharmaceutical products subject to their control are in conformity with acceptable standards of quality, safety and efficacy, and that all premises and practices employed in the manufacture, storage and distribution of these products comply with GMP standards so as to ensure the continued conformity of the products with these requirements until such time as they are delivered to the end user.

These objectives can be accomplished effectively only if a mandatory system of marketing authorization for pharmaceutical products and the licensing of their manufacturers, importing agents and distributors exists and adequate resources are available for implementation. Health authorities in countries with limited resources are less able to perform these tasks. To assure the quality of imported pharmaceutical products and drug substances, they are therefore dependent on authoritative, reliable, and independent information from the drug regulatory authority of the exporting country. This information, including information on the regulatory status of a pharmaceutical product, and the manufacturer’s compliance with GMP (2) in the exporting country, is most effectively obtained through the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce (see Annex 10), which provides a channel of communication between the regulatory authorities in the importing and exporting countries (see World Health Assembly resolutions WHA41.18 and WHA45.29).

The essential functions and responsibilities of a drug regulatory authority have been further elaborated by WHO in the guiding principles for small national drug regulatory authorities (3, 4).

2. Multisource products and interchangeability

Economic pressures often favour the use of generic products, and this can sometimes result in the purchase on contract of such products by
procurement agencies without prior licensing by the appropriate drug regulatory authority. However, all pharmaceutical products, including generic products, should be used in a country only after approval by that authority. Equally, pharmaceutical products intended exclusively for export should be subjected by the regulatory authority of the exporting country to the same controls and marketing authorization requirements with regard to quality, safety and efficacy as those intended for the domestic market in that country.

Nominally equivalent interchangeable (generic) pharmaceutical products should contain the same amount of the same therapeutically active ingredients in the same dosage form and should meet required pharmacopoeial standards. However, they are usually not identical, and in some instances their clinical interchangeability may be in question. Although differences in colour, shape and flavour are obvious and sometimes disconcerting to the patient, they are often without effect on the performance of the pharmaceutical product. However, differences in sensitizing potential due to the use of different excipients, and differences in stability and bioavailability, could have obvious clinical implications. Regulatory authorities consequently need to consider not only the quality, efficacy and safety of such pharmaceutical products, but also their interchangeability. This concept of interchangeability applies not only to the dosage form but also to the instructions for use and even to the packaging specifications, when these are critical to stability and shelf-life.

Regulatory authorities should therefore require the documentation of a generic pharmaceutical product to meet three sets of criteria relating to:

- manufacture (GMP) and quality control;
- product characteristics and labelling; and
- therapeutic equivalence (see Part Two).

Assessment of equivalence will normally require an in vivo study, or a justification that such a study is not required in a particular case. Types of in vivo studies include bioequivalence studies, pharmacodynamic studies, and comparative clinical trials (see sections 10-12). In selected cases, in vitro dissolution studies may be sufficient to provide some indication of equivalence (see section 13). The regulatory authority should be in a position to help local manufacturers by advising them on drugs that pose potential bioavailability problems so that in vivo studies are therefore required.

Examples of national requirements for in vivo studies for drugs included in the WHO Model List of Essential Drugs are given in Appendix 1.

3. **Technical data for regulatory assessment**

For pharmaceutical products indicated for standard, well established uses and containing established ingredients, the following information, inter
alia, should be provided in the documentation submitted with the application for marketing authorization and for inclusion in a computerized data retrieval system:

- the name of the product;
- the active ingredient(s) (designated by their international nonproprietary name(s)), their source, and a description of the manufacturing methods and the in-process controls;
- the type of dosage form;
- the route of administration;
- the main therapeutic category;
- a complete quantitative formula with justification and the method of manufacture of the dosage form in accordance with WHO GMP (2);
- quality control specifications for the starting materials, intermediates and final dosage form product, together with a validated analytical method;
- the results of batch testing together with the batch number and date of manufacture, including, where appropriate, the batch(es) used in bioequivalence studies;
- the indications, dosage and method of use;
- the contraindications, warnings, precautions and drug interactions;
- use in pregnancy and in other special groups of patients;
- the adverse effects;
- the effects and treatment of overdosage;
- equivalence data (comparative bioavailability, pharmacodynamic or clinical studies and comparative in vitro dissolution tests);
- stability data, proposed shelf-life, and recommended storage conditions;
- the container, packaging and labelling, including the proposed product information;
- the proposed method of distribution, e.g. as a controlled drug or a prescription item, and whether the product is intended for pharmacy sale or for general sale;
- the manufacturer and the licensing status (date of most recent inspection, date of licence and the authority that issued the licence);
- the importer/distributor;
- the regulatory status in the exporting country and, where available, summary of regulatory assessment documents from the exporting country, as well as the regulatory status in other countries.

If the dosage form is a novel one intended to modify drug delivery, e.g. a prolonged-release tablet, or if a different route of administration is proposed, supporting data, including clinical studies, will normally be required.

4. **Product information and promotion**

The product information intended for prescribers and end users should be available for all generic products authorized for marketing, and the
content of this information should be approved as a part of the marketing authorization. It should be updated in the light of current information. The wording and illustrations used in the subsequent promotion of the product should be fully consistent with this approved product information. All promotional activities should satisfy the WHO ethical criteria for medicinal drug promotion (see World Health Assembly resolution WHA41.17, 1988).

5. **Collaboration between drug regulatory authorities**

Bilateral or multilateral collaboration between drug regulatory authorities assists countries with limited resources. Sharing responsibilities in assessment and increasing mutual cooperation provide a wider spectrum of expertise for evaluation. Harmonization of the registration requirements for generics of the various drug regulatory authorities can accelerate the approval process. Furthermore, an agreed mechanism of quality assurance in relation to the assessment work of collaborating agencies is vital.

6. **Exchange of evaluation reports**

When a company applies for marketing authorization in more than one country, the exchange of evaluation reports between drug regulatory authorities on the same product from the same manufacturer can accelerate sound decision-making at the national level. Such an exchange should take place only subject to the agreement of the company concerned. Appropriate measures for safeguarding data confidentiality must be taken.

**Part Two. Equivalence studies needed for marketing authorization**

7. **Documentation of equivalence for marketing authorization**

Pharmaceutically equivalent multisource pharmaceutical products must be shown to be therapeutically equivalent to one another in order to be considered interchangeable. Several test methods are available for assessing equivalence, including:

- Comparative bioavailability (bioequivalence) studies in humans, in which the active drug substance or one or more metabolites is measured in an accessible biological fluid such as plasma, blood or urine.
- Comparative pharmacodynamic studies in humans.
- Comparative clinical trials.
- *In vitro* dissolution tests.

The applicability of each of these four methods is discussed in subsequent sections of these guidelines and special guidance is provided.
on assessing bioequivalence studies. Other methods have also been used to assess bioequivalence, e.g. bioequivalence studies in animals, but are not discussed here because they have not been accepted worldwide.

The acceptance of any test procedure in the documentation of the equivalence of two pharmaceutical products by a drug regulatory authority depends on many factors, including the characteristics of the active drug substance and the drug product, and the availability of the resources necessary for the conduct of a specific type of study. Where a drug produces meaningful concentrations in an accessible biological fluid, such as plasma, bioequivalence studies are preferred. Where a drug does not produce measurable concentrations in such a fluid, comparative clinical trials or pharmacodynamic studies may be necessary to document equivalence. \textit{In vitro} testing, preferably based on a documented \textit{in vitro/in vivo} correlation, may sometimes provide some indication of equivalence between two pharmaceutical products (see section 3).

Other criteria that indicate when equivalence studies are, or are not, necessary are discussed in sections 8 and 9 below.

8. \textbf{When equivalence studies are not necessary}

The following types of multisource pharmaceutical products are considered to be equivalent without the need for further documentation:

(a) products to be administered parenterally (e.g. by the intravenous, intramuscular, subcutaneous or intrathecal route) as aqueous solutions that contain the same active substance(s) in the same concentration(s) and the same excipients in comparable concentrations;

(b) solutions for oral use that contain the active substance in the same concentration and do not contain an excipient that is known or suspected to affect gastrointestinal transit or absorption of the active substance;

(c) gases;

(d) powders for reconstitution as a solution when the solution meets either criterion (a) or criterion (b) above;

(e) otic or ophthalmic products prepared as aqueous solutions that contain the same active substance(s) in the same concentration(s) and essentially the same excipients in comparable concentrations;

(f) topical products prepared as aqueous solutions that contain the same active substance(s) in the same concentration(s) and essentially the same excipients in comparable concentrations;

(g) inhalation products or nasal sprays that are administered with or without essentially the same device, are prepared as aqueous solutions, and contain the same active substance(s) in the same concentration(s) and essentially the same excipients in comparable concentrations. Special \textit{in vitro} testing should be required to document comparable device performance of the multisource inhalation product.
For requirements (e), (f) and (g) above, it is incumbent on the applicant to demonstrate that the excipients in the multisource product are essentially the same as, and are present in concentrations comparable to, those in the reference product. If this information about the reference product cannot be provided by the applicant, and the drug regulatory authority does not have access to these data, in vivo studies should be performed.

9. **When equivalence studies are necessary and types of studies required**

Except for the cases listed in section 8, it is recommended in these guidelines that documentation of equivalence should be requested by registration authorities for multisource pharmaceutical products. In such documentation, the product should be compared with the reference pharmaceutical product. Studies must be carried out using the formulation intended for marketing (see also Part Seven).

**In vivo studies**

For certain drugs and dosage forms, in vivo documentation of equivalence, through either a bioequivalence study, a comparative clinical pharmacodynamic study, or a comparative clinical trial, is regarded as especially important. Examples include:

(a) oral immediate-release pharmaceutical products with systemic action when one or more of the following criteria apply:

(i) indicated for serious conditions requiring assured therapeutic response;
(ii) narrow therapeutic window/safety margin; steep dose-response curve;
(iii) pharmacokinetics complicated by variable or incomplete absorption or absorption window, non-linear pharmacokinetics, presystemic elimination/high first-pass metabolism >70%;
(iv) unfavourable physicochemical properties, e.g. low solubility, instability, metastable modifications, poor permeability;
(v) documented evidence for bioavailability problems related either to the drug itself or to drugs of similar chemical structure or formulation;
(vi) high ratio of excipients to active ingredients;

(b) non-oral and non-parenteral pharmaceutical products designed to act by systemic absorption (e.g. transdermal patches, suppositories);
(c) sustained-release and other types of modified-release pharmaceutical products designed to act by systemic absorption;
(d) fixed combination products (d) with systemic action;
(e) non-solution pharmaceutical products for non-systemic use (oral, nasal, ocular, dermal, rectal, vaginal, etc.) and intended to act without systemic absorption. The concept of bioequivalence is then not
applicable, and comparative clinical or pharmacodynamic studies are required to prove equivalence. This does not, however, exclude the potential need for drug concentration measurements in order to assess unintended partial absorption.

For the first four types of pharmaceutical products, plasma concentration measurements over time (bioequivalence) are normally sufficient proof of efficacy and safety. For the last type, as already pointed out, the bioequivalence concept is not applicable, and comparative clinical or pharmacodynamic studies are required to prove equivalence.

**In vitro studies**

For certain drugs and dosage forms (see also section 13), equivalence may be assessed by means of in vitro dissolution testing. This may be considered acceptable for example for:

(a) drugs for which in vivo studies (see above) are not required;
(b) different strengths of a multisource formulation, when the pharmaceutical products are manufactured by the same manufacturer at the same manufacturing site, and:

- the qualitative composition of the different strengths is essentially the same;
- the ratio of active ingredients to excipients for the different strengths is essentially the same or, for low strengths, the ratio between the excipients is the same;
- an appropriate equivalence study has been performed on at least one of the strengths of the formulation (usually the highest strength unless a lower strength is chosen for reasons of safety); and
- in the case of systemic availability, pharmacokinetics have been shown to be linear over the therapeutic dose range.

Although these guidelines are concerned primarily with the registration requirements for multisource pharmaceutical products, it should be noted that in vitro dissolution testing may also be suitable for use in confirming that product quality and performance characteristics have remained unchanged following minor changes in formulation or manufacture after approval (see Part Six).

**Part Three. Tests for equivalence**

The bioequivalence studies, pharmacodynamic studies and clinical trials should be carried out in accordance with the provisions and prerequisites for a clinical trial, as outlined in the guidelines for good clinical practice for trials on pharmaceutical products (5) (see box), with GMP (2) and with good laboratory practice (GLP) (6).
1. **Provisions and prerequisites for a clinical trial**

1.1 **Justification for the trial**

   It is important for anyone preparing a trial of a medicinal product in humans that the specific aims, problems, and risks or benefits of a particular clinical trial be thoroughly considered and that the chosen options are scientifically sound and ethically justified.

1.2 **Ethical principles**

   All research involving human subjects should be conducted in accordance with the ethical principles contained in the current version of the Declaration of Helsinki. Three basic ethical principles should be respected, namely justice, respect for persons, and beneficence (maximizing benefits and minimizing harms and wrongs) or non-maleficence (doing no harm), as defined by the current revision of the International Ethical Guidelines for Biomedical Research Involving Human Subjects\(^1\) or the laws and regulations of the country in which the research is conducted, whichever represents the greater protection for subjects. All individuals involved in the conduct of any clinical trial must be fully informed of and comply with these principles.

1.3 **Supporting data for the investigational product**

   Pre-clinical studies that provide sufficient documentation of the potential safety of a pharmaceutical product for the intended investigational use are a prerequisite for a clinical trial. Information about manufacturing procedures and data from tests performed on the actual product should establish that it is of suitable quality for the intended investigational use. The pharmaceutical, pre-clinical and clinical data should be appropriate to the phase of the trial, and the amount of supporting data should be appropriate to the size and duration of the proposed trial. In addition, a compilation of information on the safety and efficacy of the investigational product obtained in previous and ongoing clinical trials is required for planning and conducting subsequent trials.

1.4 **Investigator and site(s) of investigation**

   Each investigator should have appropriate expertise, qualifications, and competence to undertake the proposed study. Prior to the clinical trial, the investigator(s) and the sponsor should establish an agreement on the protocol, standard operating procedures (SOP), the monitoring and auditing of the trial, and the allocation of trial-related responsibilities. The trial site should be adequate to enable the trial to be conducted safely and efficiently.

1.5 **Regulatory requirements**

   Countries in which clinical trials are performed should have regulations governing the way in which these studies can be conducted. The pre-trial agreement between the sponsor and investigator(s) should designate the parties responsible for meeting each applicable regulatory requirement (e.g., application to or notification of the trial to the relevant authority, amendments to the trial protocol, reporting of adverse events and reactions, and notifications to the ethics committee). All parties involved in a clinical trial should comply fully with the existing national regulations or requirements. In countries where regulations do not exist or require supplementation, relevant

---

\(^1\) These guidelines are updated regularly by the Council for International Organizations of Medical Sciences (CIOMS).
10. **Bioequivalence studies in humans**

Bioequivalence studies are designed to compare the *in vivo* performance of a test multisource pharmaceutical product with that of a reference pharmaceutical product. A common design for a bioequivalence study involves the administration of the test and reference products on two occasions to volunteer subjects, the second administration being separated from the first by a wash-out period of duration such as to ensure that drug given in the first treatment is entirely eliminated before the second treatment is administered. Just before administration and for a suitable period afterwards, blood and/or urine samples are collected and assayed for the concentration of the drug substance and/or one or more metabolites. The rise and fall of these concentrations over time in each subject in the study provide an indication of how the drug substance is released from the test and reference products and absorbed into the body. To allow comparisons between the two products, these blood (including
plasma or serum) and/or urine concentration-time curves are used to calculate certain bioequivalence metrics of interest. Commonly used metrics include the area under the blood (plasma or serum) concentration-time curve (AUC) and the peak concentration. These are calculated for each subject in the study and the resulting values compared statistically. Details of the general approach are given below.

Subjects

Selection of subjects
The subject population for bioequivalence studies should be as homogeneous as possible; studies should therefore generally be performed with healthy volunteers so that variability, other than in the pharmaceutical products concerned, is reduced. Clear criteria for inclusion/exclusion should be established. If possible, subjects should be of both sexes; however, the risk to women will need to be considered on an individual basis and, if necessary, they should be warned of any possible dangers to the fetus if they should become pregnant. They should normally be in the age range 18-55 years and of weight within the normal range according to accepted life tables. Subjects should preferably be non-smokers and without a history of alcohol or drug abuse. If smokers are included, they should be identified as such. Volunteers should be screened for suitability by means of standard laboratory tests, a medical history, and a physical examination. If necessary, special medical investigations may be carried out before and during studies, depending on the pharmacology of the drug being investigated.

If the aim of the bioequivalence study is to address specific questions (e.g. bioequivalence in a special population), the selection criteria will have to be adjusted accordingly.

Genetic phenotyping
Phenotyping and/or genotyping of subjects may be considered for safety reasons.

Patients versus healthy volunteers
If the active substance is known to have adverse effects and the pharmacological effects or risks are considered unacceptable for healthy volunteers, it may be necessary to use patients under treatment instead. This alternative should be explained by the sponsor.

Monitoring the health of subjects during the study
During the study, the health of volunteers should be monitored so that the onset of side-effects, toxicity, or any intercurrent disease may be recorded, and appropriate measures taken. Health monitoring before, during and after the study must be carried out under the supervision of a qualified medical practitioner licensed in the jurisdiction in which the study is conducted.
Design

General study design
The study should be designed so that the test conditions are such as to reduce intra- and intersubject variability and avoid biased results. Standardization of exercise, diet, fluid intake and posture, and restriction of the intake of alcohol, caffeine, certain fruit juices, and drugs other than that being studied in the period before and during the study are important in order to minimize the variability of all the factors involved except that of the pharmaceutical product(s) being tested.

A cross-over design with randomized allocation of volunteers to each leg is the first choice for bioequivalence studies. Study design should, however, depend on the type of drug, and other designs may be more appropriate in certain cases, e.g. with highly variable drugs and those with a long half-life. In cross-over studies, a wash-out period between the administration of the test product and that of the reference product of more than five times the half-life of the dominant drug is usual, but special consideration will need to be given to extending this period if active metabolites with longer half-lives are produced, and also under certain other circumstances.

The administration of the test product should be standardized, i.e. the time of day for ingestion and the volume of fluid (150 ml is usual) should be specified. Test products are usually administered in the fasting state.

Parameters to be assessed
In bioavailability studies, the shape of, and the area under, the plasma concentration curve, or the profile of cumulative renal excretion and excretion rate are commonly used to assess the extent and rate of absorption. Sampling points or periods should be chosen such that the time-concentration profile is adequately defined so as to allow the calculation of relevant parameters. From the primary results, the bioavailability parameters desired, e.g. $AUC_\infty$, $AUC_t$, $C_{max}$, $t_{max}$, $Ae_\infty$, $Ae_t$, $dAe/dt$, or any other necessary parameters, are derived (see Appendix 2). The method of calculating AUC-values should be specified. $AUC_\infty$ and $C_{max}$ are considered to be the most useful parameters for the assessment of bioequivalence. For urine excretion data, the corresponding parameters are $Ae_\infty$ and $dAe/dt_{max}$. For additional information, $t_{1/2}$ and MRT can be calculated, and for steady-state studies, $AUC_t$ and the per cent peak-trough fluctuation. The exclusive use of modelled parameters is not recommended unless the pharmacokinetic model has been validated for the active substance and the products.

Additional considerations for complicated drugs
For drugs which would cause unacceptable pharmacological effects (e.g. serious adverse events) in volunteers or where the drug is toxic or particularly potent or the trial necessitates a high dose, cross-over or parallel-group studies in patients may be required.
Drugs with long half-lives may require a parallel design or the use of truncated area under curve (AUC) data or a multidose study. The truncated area should cover the absorption phase.

For drugs for which the rate of input into the systemic circulation is important, more samples may have to be collected around the time $t_{\text{max}}$.

Multidose studies may be helpful in assessing bioequivalence for:

- drugs with non-linear kinetics (including those with saturable plasma protein binding);
- drugs for which the assay sensitivity is too low to cover a large enough portion of AUC$_{\text{a}}$;
- drug substance combinations, if the ratio of the plasma concentration of the individual drug substances is important;
- controlled-release dosage forms;
- highly variable drugs.

**Number of subjects**

The number of subjects required for a sound bioequivalence study is determined by the error variance associated with the primary parameters to be studied (as estimated from a pilot experiment, from previous studies or from published data), by the significance level desired, and by the deviation from the reference product compatible with bioequivalence, safety and efficacy. It should be calculated by appropriate methods (see p. 131) and should not normally be smaller than 12. In most studies, 18–24 subjects will be needed (7–9). The number of subjects recruited should always be justified.

**Investigational products**

The products (samples) used in bioequivalence studies for registration purposes should be identical to the projected commercial pharmaceutical product. For this reason, not only the composition and quality characteristics (including stability) but also the methods of manufacture should be those to be used in future routine production runs.

Samples should ideally be taken from industrial-scale batches. When this is not feasible, pilot- or small-scale production batches may be used provided that they are not less than one-tenth (10%) of the size of the expected full-scale production batches.

It is recommended that the potency and *in vitro* dissolution characteristics of the test and reference pharmaceutical products should be ascertained before an equivalence study is performed. The content of active drug substance(s) in the two products should not differ by more than ±5%. If the potency of the reference material deviates by more than 5% from that corresponding to the declared content of 100%, this difference may be used subsequently to dose-normalize certain bioavailability metrics in order to facilitate comparisons between the test and reference pharmaceutical products.
Studies of metabolites
The use of metabolite data in bioequivalence studies requires careful consideration. The evaluation of bioequivalence will generally be based on the measured concentrations of the pharmacologically active drug substance and its active metabolite(s), if present. If it is impossible to measure the concentration of the active drug substance, that of a major biotransformation product may be measured instead, while measurement of the concentration of such a product is essential if the substance studied is a prodrug. If urinary excretion (rate) is measured, the product determined should represent a major fraction of the dose. Although measurement of a major active metabolite is usually acceptable, that of an inactive metabolite can only rarely be justified.

Measurement of individual isomers for chiral drug substance products
A non-stereoselective assay is currently acceptable for bioequivalence studies. Under certain circumstances, however, assays that distinguish between the enantiomers of a chiral drug substance may be appropriate.

Validation of analytical procedures
All analytical procedures must be well characterized, fully validated and documented, and satisfy the relevant requirements as to specificity, accuracy, sensitivity and precision. Knowledge of the stability of the active substance and/or biotransformation product in the sample material is a prerequisite for obtaining reliable results (10). It should be noted that:

- validation comprises both before-study and within-study phases;
- validation must cover the intended use of the assay;
- the calibration range must be appropriate to the study samples;
- if an assay is to be used at different sites, it must be validated at each site and cross-site comparability established;
- an assay which is not in regular use requires sufficient revalidation to show that it is performed according to the original validated procedures; the revalidation study must be documented usually as an appendix to the study report;
- within a given study, the use of two or more methods to assay samples in the same matrix over a similar calibration range is strongly discouraged;
- if different studies are to be compared, the samples from these studies have been assayed by different methods, and the methods cover a similar concentration range and the same matrix, they should be cross-validated.

The results of validation should be reported.

Reserve samples
Sufficient samples of each batch of the pharmaceutical products used in the studies, together with a record of their analyses and characteristics,
must be kept for reference purposes under appropriate storage conditions as specified by national regulations. At the specific request of the competent authorities, these reserve samples may be handed over to them so that they can recheck the products.

**Statistical analysis and acceptance criteria**

**General consideration**

The primary concern in bioequivalence assessment is to limit the risk $(\alpha)$ of a false declaration of equivalence to that which the regulatory authorities are willing to accept.

The statistical methods of choice at present are the two one-sided tests procedure (11) and the derivation of a parametric or non-parametric $100(1-2\alpha)\%$ confidence interval for the quotient $\mu_H/\mu_R$ of the test and reference pharmaceutical products. The value of $\alpha$ is set at 5%, leading, in the parametric case, to the shortest (conventional) 90% confidence interval based on an analysis of variance or, in the non-parametric case, to the 90% confidence interval (12, 13).

The statistical procedures should be specified before data collection starts (see Appendix 3), and should lead to a decision scheme which is symmetrical with respect to the two formulations, i.e. it should lead to the same decision whether the new formulation is compared with the reference product or vice versa.

Concentration and concentration-related quantities e.g. AUC and $C_{max}$ should be analysed after logarithmic transformation, but $t_{max}$ will usually be analysed without such transformation.

For $t_{max}$, normally descriptive statistics should be given. If $t_{max}$ is to be subjected to a statistical analysis, this should be based on non-parametric methods. Other parameters may also be evaluated by non-parametric methods, when descriptive statistics should be given that do not require specific distributional assumptions, e.g. medians instead of means.

The assumptions underlying the design or analysis should be addressed, and the possibility of differing variations in the formulations should be investigated. This covers the investigation of period effects, sequence or carry-over effects, and homogeneity of variance.

The impact of outlying observations on the conclusions should be reviewed. Medical or pharmacokinetic explanations for such observations should be sought.

**Acceptance ranges**

For AUC, the 90% confidence interval should generally be within the acceptance range 80–125%. For drugs with a particularly narrow therapeutic range, the AUC acceptance range may need to be smaller; this should be justified clinically.
$C_{\text{max}}$ does not characterize the rate of absorption particularly well in many cases, but there is no consensus on any other concentration-based parameter which might be more suitable. The acceptance range for $C_{\text{max}}$ may be wider than that for AUC (see Appendix 3).

**Reporting of results**

The report on a bioequivalence study should give the complete documentation of its protocol, conduct and evaluation in compliance with the guidelines on good clinical practice (GCP) for trials on pharmaceutical products (5). The responsible investigator(s) should sign the respective section(s) of the report. The names and affiliations of the responsible investigator(s), the site of the study and the period of its execution should be stated. The names and batch numbers of the pharmaceutical products used in the study, as well as the composition(s) of the tests product(s), should also be given. The analytical validation report should be attached. The results of *in vitro* dissolution tests should be provided. In addition, the applicant for registration should submit a signed statement confirming that the test product is identical with the pharmaceutical product submitted.

All results should be clearly presented. The procedure for calculating the parameters used (e.g. AUC) from the raw data should be stated. Deletion of data should be justified. If results are calculated using pharmacokinetic models, the model and the computing procedure used should be justified. Individual plasma concentration-time curves should be drawn on a linear/linear scale, and may also be shown on a linear/log scale. All individual data and results should be given, including those for any subjects who have dropped out of the trial. Drop-out and withdrawal of subjects should be reported and accounted for. Test results on representative samples should be included.

The statistical report should be sufficiently detailed to enable the statistical analyses to be repeated, if necessary. If the statistical methods applied deviate from those specified in the trial protocol, the reasons for the deviations should be stated.

11. **Pharmacodynamic studies**

Pharmacodynamic measurements in healthy volunteers or patients may be used for establishing equivalence between two pharmaceutical products. This may be necessary if the drug and/or its metabolite(s) in plasma or urine cannot be determined quantitatively with sufficient accuracy and sensitivity. Furthermore, pharmacodynamic studies in humans are required if measurements of drug concentrations cannot be used as surrogate end-points for the demonstration of the efficacy and safety of the particular pharmaceutical product; this applies, for example, to topical products where it is not intended that the drug should be absorbed into the systemic circulation.
If pharmacodynamic studies are used, the conditions under which they are performed must be as rigorously controlled as those of bioequivalence studies, and the requirements of the guidelines for good clinical practice (GCP) for trials on pharmaceutical products (5) must be satisfied.

The following requirements must be taken into account in planning, conducting and assessing the results of a study intended to demonstrate equivalence by means of measurements of pharmacodynamic drug responses:

- the response measured should be a pharmacological or therapeutic effect relevant to the claims of efficacy and/or safety;
- the methodology must be validated for precision, accuracy, reproducibility and specificity;
- neither the test nor the reference product should produce a maximum response in the course of the study, since it may be impossible to distinguish differences between formulations given in doses that produce maximum or near-maximum effects; investigation of dose-response relationships may be a necessary part of the design;
- the response should be measured quantitatively under double-blind conditions and be recordable by means of a suitable instrument on a repetitive basis to provide a record of the pharmacodynamic events which are substitutes for plasma concentrations; where such measurements are not possible, recordings on visual analogue scales may be used, and where the data are limited to qualitative (categorized) measurements, appropriate special statistical analysis will be required;
- non-responders should be excluded from the study by prior screening, and the criteria whereby responders and non-responders are identified must be stated in the protocol;
- where an important placebo effect can occur, allowance for this effect should be made in the study design by including placebo treatment as a third phase in that design;
- the underlying pathology and natural history of the condition should be considered in the study design, and information on the reproducibility of baseline conditions should be available;
- where a cross-over design is not appropriate, a parallel group study design should be chosen.

In studies in which continuous variables can be recorded, the time course of the intensity of the drug action can be described in the same way as in a study in which plasma concentrations are measured, and parameters can be derived which describe the area under the effect–time curve, the maximum response and the time when that response occurred.

The statistical methods for the assessment of the outcome of the study are, in principle, the same as those outlined for bioequivalence studies. However, a correction should be made for the potential non-linearity of
the relationship between the dose and the area under the effect-time curve, based on the outcome of a dose-response study. However, it should be noted that the conventional acceptance range as applied for bioequivalence assessment is usually too large and therefore not appropriate; for this reason, it should be defined on a case-by-case basis and described in the protocol.

12. Clinical trials

For certain drugs and dosage forms (see example (e), pp. 123-124) plasma concentration time-profile data are not suitable for use in assessing equivalence between two formulations. While pharmacodynamic studies can sometimes be an appropriate tool for establishing equivalence (see section 11), in other instances this type of study cannot be performed because of a lack of meaningful and measurable pharmacodynamic parameters; a comparative clinical trial must then be performed in order to demonstrate equivalence between two formulations. In such a clinical trial, the same statistical principles will apply as in bioequivalence studies. The number of patients to be included in the study will depend on the variability of the target parameters and the acceptance range, and is usually much higher than that required in bioequivalence studies.

The methodology to be used in establishing equivalence between pharmaceutical products by means of a clinical trial in patients in which there is a therapeutic end-point has not yet been discussed as extensively as that used in bioequivalence trials. However, the following are important and need to be defined in the protocol:

(a) The target parameters; these are usually relevant clinical end-points from which the intensity and the onset, if applicable and relevant, of the response can be derived.

(b) The size of the acceptance range; this must be defined on a case-by-case basis, taking into consideration the specific clinical conditions, for example the natural course of the disease, the efficacy of available treatments and the chosen target parameter. In contrast to bioequivalence studies (where a conventional acceptance range is used), the size of the acceptance range in clinical trials cannot be based on a general consensus on all the therapeutic classes and indications.

(c) The statistical method used; this is currently the confidence interval approach, the main concern being to rule out the possibility that the test product is inferior to the reference pharmaceutical product by more than the specified amount. A one-sided confidence interval (for efficacy and/or safety) may therefore be appropriate. The confidence intervals can be derived by either parametric or non-parametric methods.
Where appropriate, a placebo leg should be included in the design, and it is sometimes appropriate to include safety end-points in the final comparative assessments.

13. *In vitro* dissolution

Comparative *in vitro* dissolution studies may be useful in the documentation of equivalence between two multisource pharmaceutical products. However, because of the many limitations associated with the use of *in vitro* dissolution in the documentation of equivalence it is recommended in these guidelines that its application for this purpose should be kept to a minimum. *In vitro* dissolution testing as the sole documentation of equivalence is therefore not applicable to the drugs and dosage forms listed as examples (a)-(e) on p. 123, but should be reserved for rapidly dissolving drug products.¹ When the multisource test and reference products both dissolve with sufficient rapidity (e.g., >80% in 15 minutes), their *in vivo* equivalence may be presumed. Approval of multisource formulations by the use of comparative *in vitro* dissolution studies should be based on the generation of comparative dissolution profiles rather than single-point dissolution tests, as described in various pharmacopoeial compendia and other publications. Multiple dissolution test conditions and physiologically relevant media are recommended.

---

**Part Four. In vitro dissolution tests in product development and quality control**

*In vitro* dissolution tests are useful in product development and in monitoring the batch-to-batch consistency of the manufacturing process following approval of marketing. Such tests are also used to check the consistency of the release characteristics of a dosage form during storage. Dissolution testing may also provide a useful check on a number of characteristics of the dosage form, including:

- the particle size distribution, state of hydration, crystal form and other solid state properties of the active ingredients;

¹ Where a drug substance and drug product do not dissolve with sufficient rapidity, as noted above, *in vitro* dissolution methods may still be used to document equivalence using appropriately validated dissolution methodology including an *in vitro*-in *vivo* correlation. Such methodology should be derived from the development and application of specifications and statistical methods to define non-equivalence. This may require formulations with different in *vivo* performance characteristics. With such formulations, discriminatory *in vitro* dissolution tests for use in equivalence studies may be developed. With these additional requirements, however, a standard *in vivo* bioequivalence study as described in section 7 may be preferable.
— the mechanical properties of the dosage form itself (water content, resistance to crushing force for tablets, integrity of the shell for capsules and coated tablets, etc.).

When used in product quality control, information on in vitro dissolution should be provided in the documentation submitted with the application for marketing authorization. In vitro dissolution tests and quality control specifications should be based either on suitable compendial specifications or on the in vitro performance of the test batches used to generate material for the equivalence study. Where sufficient full-scale process validation batches are not prepared in the immediate post-approval period, several batches (two or three are recommended) of the test product should be manufactured in the preapproval period in accordance with standard, consistent, well documented procedures. Two of these batches should contain at least 100,000 units or 10% of the intended production batch, whichever is larger. The third, if prepared, may be smaller (e.g. 25,000 units). The use of smaller batches should be justified. Material from these test batches is used to provide material both for dissolution studies and for equivalence testing. Physiologically relevant media and test conditions should be used for dissolution tests on these batches. When selecting the test methods to be used, it is recommended that widely used compendial methods (“paddle” and “basket”) should be used initially and other methods (“flow-through cell”, etc.) tried if these fail to demonstrate sufficient discriminatory power. Dissolution profiles are recommended, even when a single-point compendial dissolution test is available. For immediate-release pharmaceutical products, a single-point dissolution test may be used for quality control purposes. Specifications for the dissolution performance of batches subsequently manufactured will be based on the results of the dissolution tests performed on the test batches. While it is undisputed that the value of dissolution testing will be increased if the test results can be shown by in vivo studies to reflect important changes in formulation and/or the manufacturing process, the practical problems involved are still under discussion. It is not recommended that the dissolution specification should be made less stringent on the basis of the performance of the test batches beyond the point where equivalence between the test material used in the equivalence study and production batches subsequently manufactured can no longer be assumed.

The following data should be recorded and included in the documentation submitted with the application for marketing authorization:

(a) comparative dissolution results for the test and reference pharmaceutical products after intervals appropriate for the products and conditions under investigation (a minimum of three sampling times is normal);
(b) for each sampling time, the observed data, individual values, the range and the coefficient of variation (relative standard deviation).
Part Five. Clinically important variations in bioavailability leading to non-approval of the product

A new formulation of bioavailability outside the acceptance range as compared with an existing pharmaceutical product is by definition not interchangeable. A marketing authorization for a formulation of lower bioavailability may not be approved because of efficacy concerns. In contrast, a formulation of higher bioavailability ("suprabioavailability") may not be approved because of safety concerns. There are then the following two options:

1. The suprabioavailable dosage form, if reformulated so as to be bioequivalent to the existing pharmaceutical product, could be accepted as interchangeable with that product. This may not be ideal, however, as dosage forms of lower bioavailability tend to be variable in performance.

2. A dosage form of increased bioavailability in which the content of active substance has been appropriately reduced could be accepted as a new (improved) dosage form, but this decision would normally need to be supported by clinical trial data. Such a pharmaceutical product must not be accepted as interchangeable with the existing pharmaceutical product, and would normally become the reference product for future interchangeable pharmaceutical products. The name of the new pharmaceutical product should be such as to preclude confusion with the older approved pharmaceutical product(s).

Part Six. Studies needed to support new post-marketing manufacturing conditions

With all pharmaceutical products, when post-marketing changes are made, extensive in vitro and/or in vivo testing may be required. Such changes may be in: (i) formulation; (ii) site of manufacture; (iii) manufacturing process; and (iv) manufacturing equipment. The types and extent of the further testing required will depend on the magnitude of the changes made. If a major change is made, the product might then become a new pharmaceutical product, if the national regulatory authorities so decide.

Part Seven. Choice of reference product

The innovator pharmaceutical product is usually the most logical reference product for related generics because, in general, its quality will have been well assessed and its efficacy and safety will have been securely established in clinical trials and post-marketing monitoring
schemes. There is, however, currently no global agreement on the selection of reference products, which are selected at national level by the drug regulatory authority. Either the most widely used “leading” pharmaceutical product in the market or the product that was first approved in that market is normally chosen. It is therefore possible that significant differences may exist between the reference products adopted in different countries.

This being so, consideration needs to be given to the feasibility of developing reference products on a global basis. Representative bodies of the pharmaceutical industry and other interested parties should be invited to collaborate in the preparation, maintenance and international acceptance of a system of international reference standards for pharmaceutical products of defined quality and bioavailability.

Authors

The guidelines were developed during three meetings convened by the Division of Drug Management and Policies, World Health Organization, Geneva, Switzerland, on 18–19 February 1993, 23–27 August 1993, and 23–26 August 1994, attended by the following people:

Professor J.-M. Aliache, University of Clermont-Ferrand, Clermont-Ferrand, France
Dr Andayaningsih, Ministry of Health, Jakarta, Indonesia
Dr N. Aoyagi, National Institute of Health Sciences, Tokyo, Japan
Dr E. Beyssac, University of Clermont-Ferrand, Clermont-Ferrand, France
Professor D. Birkett, Flinders Medical Centre, Bedford Park, Australia
Dr D. Blois, International Federation of Pharmaceutical Manufacturers Associations (IFPMA), Geneva, Switzerland
Professor H. Blume, International Pharmaceutical Federation (FIP), Eschborn, Germany
Professor A. Bonani, General Directorate for the Control of Health Inputs, Mexico City, Mexico
Miss M. Cone, International Federation of Pharmaceutical Manufacturers Associations (IFPMA), Geneva, Switzerland
Mr M. N. Dauramanzi, Drugs Control Council, Harare, Zimbabwe
Mr T. Fushimi, Ministry of Health and Welfare, Tokyo, Japan
Professor U. Gundert-Remy (Chairman), Department of Clinical Pharmacology, University of Göttingen, Göttingen, Germany
Dr C. G. Guyer, Food and Drug Administration, Rockville, MD, USA
Professor F. D. Juma, University of Nairobi, Nairobi, Kenya
Professor G. Kreutz, Federal Institute for Drugs and Medicinal Devices, Berlin, Germany
Dr L. Lacy, International Federation of Pharmaceutical Manufacturers Associations (IFPMA), Geneva, Switzerland
Dr I. J. McGilveray, Drugs Directorate, Ottawa, Canada
Dr O. Morin, International Federation of Pharmaceutical Manufacturers Associations (IFPMA), Geneva, Switzerland
Dr R. Nedic, Generic Pharmaceutical Industry Association, Washington, DC, USA
Dr A. Nijkerk, European Generic Medicines Association, Brussels, Belgium
Dr H. P. Osterwald, European Generic Medicines Association, Brussels, Belgium
Professor T. L. Paál, National Institute of Pharmacy, Budapest, Hungary
Dr R. N. Patnaik, Food and Drug Administration, Rockville, MD, USA
Dr J. M. Peón, General Directorate for the Control of Health Inputs, Mexico City, Mexico
Miss M.-C. Pickaert, International Federation of Pharmaceutical Manufacturers Associations (IFPMA), Geneva, Switzerland
Professor L. Rägo, State Agency of Medicines, Tartu, Estonia
Dr B. Rosenkrantz, International Federation of Pharmaceutical Manufacturers Associations (IFPMA), Geneva, Switzerland
Dr H. Scheinin, Turku University Central Hospital, Turku, Finland
Mr N. Uemura, Ministry of Health, Tokyo, Japan
Professor B. Vrhovac, University Hospital Medical School, Zagreb, Croatia
Dr R. L. Williams, Food and Drug Administration, Rockville, MD, USA

Secretariat (WHO, Geneva, Switzerland)
Dr J. F. Dunne, Director, Division of Drug Management and Policies
Dr J. Idänpää-Heikilä, Associate Director, Division of Drug Management and Policies

References


Appendix 1

Examples of national requirements for in vivo equivalence studies for drugs included in the WHO Model List of Essential Drugs (Canada, Germany and the USA, December 1994)

General

National requirements for equivalence studies for specific drug products differ from country to country. National requirements for equivalence studies of a specific drug product can be based on any of the following:

- case-by-case study;
- criteria established by a national advisory committee; or
- application of the national regulatory guidelines.

A list of examples is presented in Table 1. It is intended to be illustrative only, in accordance with the guidelines, and does not represent a formal recommendation.

The list is based on substances and products included in the WHO Model List of Essential Drugs (1), but only includes essential drugs for which in vivo studies are required because of the nature of the dosage form. Some dosage forms, e.g. solutions and injections, have therefore been omitted from the list as they have not been identified as requiring studies in one of the three countries covered.

Examples of decisions on criteria taken by national authorities

Canada

At present, demonstration of bioequivalence is required for those drugs which are not considered to have been marketed in Canada for their intended purpose(s) for sufficient time and in sufficient quantity to establish safety and efficacy (new drugs). Bioequivalence may be demonstrated by comparative bioequivalence studies or by clinical studies including, where applicable, acceptable surrogate models. Scientific criteria, similar to those of the European Community and Australia, are being developed for deciding in which situations in vivo demonstration of bioequivalence is required for drugs that are not new.

Germany

Over the past years, the National Advisory Committee has taken the decision on the need for a comparative bioavailability/bioequivalence study as a requirement for marketing authorization. These decisions have been based on published data for the drug substance and its dosage form, and on the use of an algorithm. Details of the algorithm, the criteria and the resulting decisions have been published in the German Federal Register. In certain circumstances, the regulatory authority takes decisions on a case-by-case basis.
USA
Drug products introduced before 1938 in the USA do not require approval for marketing and therefore no in vivo equivalence study is needed. The majority of drug products, other than solution dosage forms, approved between 1938 and 1962, and known to have potential bioavailability problems, require in vivo equivalence studies. Generally, drug products approved after 1962, with the exception of solution dosage forms, also require in vivo equivalence studies.

Table 1
Examples of national requirements for equivalence studies

<table>
<thead>
<tr>
<th>Drug substance</th>
<th>Dosage form</th>
<th>Canada</th>
<th>Germany</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>acetazolamide</td>
<td>tablet, 250 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>acetylsalicylic acid</td>
<td>suppository, 50-150 mg</td>
<td>?</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>tablet, 100-500 mg</td>
<td>-</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>albendazole</td>
<td>tablet, 200 mg</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>allopurinol</td>
<td>tablet, 100 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>aluminium hydroxide</td>
<td>oral suspension, 320 mg/5 ml</td>
<td>-</td>
<td>+p</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>tablet, 500 mg</td>
<td>-</td>
<td>+p</td>
<td>-</td>
</tr>
<tr>
<td>amiloride hydrochloride</td>
<td>tablet, 5 mg</td>
<td>+b</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>aminobenzoic acid</td>
<td>cream</td>
<td>?</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>gel</td>
<td>?</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>lotion</td>
<td>?</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td>aminophylline</td>
<td>tablet, 100 mg, 200 mg</td>
<td>?</td>
<td>o</td>
<td>+b</td>
</tr>
<tr>
<td>amitriptyline hydrochloride</td>
<td>tablet, 25 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>amoxicillin</td>
<td>capsule, 250 mg, 500 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>powder for oral suspension, 125 mg/5 ml</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 250 mg, 500 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>ascorbic acid</td>
<td>tablet, 50 mg</td>
<td>-</td>
<td>?</td>
<td>-</td>
</tr>
<tr>
<td>atenolol</td>
<td>tablet, 50 mg, 100 mg</td>
<td>+b</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>atropine sulfate</td>
<td>solution (eye drops), 0.1%, 0.5%, 1%</td>
<td>o</td>
<td>+c</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>tablet, 1 mg</td>
<td>o</td>
<td>?</td>
<td>o</td>
</tr>
<tr>
<td>azathioprine</td>
<td>tablet, 50 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
</tbody>
</table>

1: +: in vivo studies required; +b: bioequivalence studies; +p: pharmacodynamic studies; +c: clinical trials; -: no in vivo studies required; ?: decision on the type of in vivo studies pending; o: no information available, no final decision taken, or not available on national market. See also pp. 124-135.
<table>
<thead>
<tr>
<th>Drug substance</th>
<th>Dosage form</th>
<th>Canada</th>
<th>Germany</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>bacitracin zinc</td>
<td>ointment, 500 IU + neomycin sulfate, 5 mg/g</td>
<td>0</td>
<td>+c</td>
<td>-</td>
</tr>
<tr>
<td>beclomethasone dipropionate</td>
<td>inhalation, 50 µg/dose</td>
<td>?</td>
<td>+p+c</td>
<td>+p</td>
</tr>
<tr>
<td>benzathine benzylpenicillin</td>
<td>powder for injection, 1.44 g of benzylpenicillin (= 2.4 million IU) in 5-ml vials</td>
<td>c</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>benznidazole</td>
<td>tablet, 100 mg</td>
<td>0</td>
<td>+b</td>
<td>0</td>
</tr>
<tr>
<td>benzoic acid</td>
<td>cream, 6% + salicylic acid, 3%</td>
<td>-</td>
<td>+p+c</td>
<td>0</td>
</tr>
<tr>
<td>benzoyl peroxide</td>
<td>cream, 5%</td>
<td>-</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td>benzyl benzoate</td>
<td>lotion, 5%</td>
<td>-</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td>betamethasone</td>
<td>cream, 0.1% of betamethasone</td>
<td>+p</td>
<td>+p+c</td>
<td>+p</td>
</tr>
<tr>
<td>valerate</td>
<td>ointment, 0.1% of betamethasone</td>
<td>+p</td>
<td>+p+c</td>
<td>+p</td>
</tr>
<tr>
<td>biperiden hydrochloride</td>
<td>tablet, 2 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>calamine</td>
<td>lotion</td>
<td>-</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td>calcium folinate</td>
<td>tablet, 15 mg</td>
<td>+b</td>
<td>0</td>
<td>+b</td>
</tr>
<tr>
<td>captopril</td>
<td>tablet, 25 mg</td>
<td>+b</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>carbamazepine</td>
<td>tablet, 100 mg, 200 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>carbidopa</td>
<td>tablet, 10 mg + levodopa, 100 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>25 mg + levodopa, 250 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>chloramphenicol</td>
<td>capsule, 250 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>chloramphenicol palmitate</td>
<td>oral suspension, 150 mg of chloramphenicol/5 ml</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>chloramphenicol sodium succinate</td>
<td>oily suspension, injection 0.5 g of chloramphenicol/ml in 2-ml ampoule</td>
<td>0</td>
<td>+b</td>
<td>c</td>
</tr>
<tr>
<td>chloroquine hydrochloride</td>
<td>injection, 40 mg of chloroquine/ml</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>in 5-ml ampoule</td>
<td></td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>chloroquine phosphate</td>
<td>tablet, 150 mg of chloroquine</td>
<td>0</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>chloroquine sulfate</td>
<td>tablet, 150 mg of chloroquine</td>
<td>0</td>
<td>+b</td>
<td>0</td>
</tr>
</tbody>
</table>

1: +: in vivo studies required; +b: bioequivalence studies; +p: pharmacodynamic studies; +c: clinical trials; -: no in vivo studies required; ?: decision on the type of in vivo studies pending; 0: no information available, no final decision taken; o: not available on national market. See also pp. 124–135.
Table 1 (continued)

Examples of national requirements for equivalence studies

<table>
<thead>
<tr>
<th>Drug substance</th>
<th>Dosage form</th>
<th>Canada</th>
<th>Germany</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>chlorphenamine hydrogen maleate</td>
<td>tablet, 4 mg</td>
<td>-</td>
<td>?</td>
<td>-</td>
</tr>
<tr>
<td>chlorpromazine hydrochloride</td>
<td>tablet, 100 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>ciclosporin</td>
<td>capsule, 25 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>cimetidine</td>
<td>tablet, 200 mg</td>
<td>+b</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>ciprofloxacin hydrochloride</td>
<td>tablet, 250 mg of ciprofloxacin</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>clofazimine</td>
<td>capsule, 50 mg, 100 mg</td>
<td>o</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>clomifene citrate</td>
<td>tablet, 50 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>clomipramine hydrochloride</td>
<td>capsule, 10 mg, 25 mg</td>
<td>+b</td>
<td>o</td>
<td>+b</td>
</tr>
<tr>
<td>cloxacillin sodium</td>
<td>capsule, 500 mg of cloxacillin</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>codeine phosphate</td>
<td>tablet, 10 mg, 30 mg</td>
<td>o</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>colchicine</td>
<td>tablet, 500 µg</td>
<td>?</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>cyclophosphamide</td>
<td>tablet, 25 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>dapsone</td>
<td>tablet, 50 mg, 100 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>desmopressin acetate</td>
<td>nasal spray, 10 µg/metered dose</td>
<td>+b+p</td>
<td>+p+c</td>
<td>?</td>
</tr>
<tr>
<td>dexamethasone</td>
<td>tablet, 500 µg, 4 mg</td>
<td>?</td>
<td>?</td>
<td>+b</td>
</tr>
<tr>
<td>diazepam</td>
<td>scored tablet, 2 mg, 5 mg</td>
<td>+b</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>diethy/Carbamazine dihydrogen citrate</td>
<td>tablet, 50 mg</td>
<td>o</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>digitoxin</td>
<td>tablet, 50 µg, 100 µg</td>
<td>?</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>digoxin</td>
<td>tablet, 62.5 µg, 250 µg</td>
<td>?</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>diloxanide furoate</td>
<td>tablet, 500 mg</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>dimercaprol</td>
<td>injection, in oil 50, mg/ml in 2-ml ampoule</td>
<td>+b+c</td>
<td>+b\textsuperscript{2}</td>
<td>-</td>
</tr>
<tr>
<td>dihydrobenzone</td>
<td>cream</td>
<td>?</td>
<td>+p+c</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td>lotion</td>
<td>?</td>
<td>+p+c</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td>gel</td>
<td>?</td>
<td>+p+c</td>
<td>o</td>
</tr>
<tr>
<td>dithranol</td>
<td>ointment, 0.1-2%</td>
<td>-</td>
<td>+p+c</td>
<td>-</td>
</tr>
</tbody>
</table>

\textsuperscript{1} +: in vivo studies required; +b: bioequivalence studies; +p: pharmacodynamic studies; +c: clinical trials; -: no in vivo studies required; ?: decision on the type of in vivo studies pending; o: no information available, no final decision taken, or not available on national market. See also pp. 124–135.

\textsuperscript{2} "Depot" preparation for injection.
Table 1 (continued)
Examples of national requirements for equivalence studies

<table>
<thead>
<tr>
<th>Drug substance</th>
<th>Dosage form</th>
<th>Canada</th>
<th>Germany</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>doxycycline hyclate</td>
<td>capsule, 100 mg of doxycycline +b</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 100 mg of doxycycline +b</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>ergocalciferol</td>
<td>capsule, 1.25 mg (50,000 IU) o</td>
<td>+b</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>tablet, 1.25 mg (50,000 IU) o</td>
<td>+b</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ergometrine hydrogen maleate</td>
<td>tablet, 200 µg</td>
<td>?</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>ergotamine tartrate</td>
<td>tablet, 2 mg</td>
<td>o</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>erythromycin</td>
<td>capsule, 250 mg of erythromycin +b</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>ethylsuccinate</td>
<td>powder for oral suspension, 125 mg of erythromycin</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 250 mg of erythromycin +b</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>erythromycin stearate</td>
<td>capsule, 250 mg of erythromycin +b</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>powder for oral suspension, 125 mg of erythromycin</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 250 mg of erythromycin +b</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>ethambutol</td>
<td>tablet, 100-400 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>hydrochloride</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ethinylestradiol</td>
<td>tablet, 50 µg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 30 µg + levonorgestrel +b</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>150 µg</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>50 µg + levonorgestrel, 250 µg +b</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 35 µg + norethisterone, 1.0 mg +b</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>ethosuximide</td>
<td>capsule, 250 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>etoposide</td>
<td>capsule, 100 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>ferrous sulfate</td>
<td>tablet, 80 mg of Fe</td>
<td>-</td>
<td>o</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>tablet, 60 mg of Fe + folic acid, 250 µg</td>
<td>-</td>
<td>o</td>
<td>-</td>
</tr>
<tr>
<td>flucytosine</td>
<td>capsule, 250 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>fluodrocortisone acetate</td>
<td>tablet, 100 µg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>fluorouracil</td>
<td>ointment, 5%</td>
<td>+c</td>
<td>+p+c</td>
<td>?</td>
</tr>
<tr>
<td>fluphenazine decanoate</td>
<td>injection, 25 mg in 1-ml ampoule +b</td>
<td>+b²</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td></td>
<td>injection, 25 mg in 1-ml ampoule +b²</td>
<td>+b²</td>
<td>-</td>
<td></td>
</tr>
</tbody>
</table>

1: in vivo studies required; +b: bioequivalence studies; +p: pharmacodynamic studies; +c: clinical trials; -: no in vivo studies required; ?: decision on the type of in vivo studies pending; o: no information available, no final decision taken, or not available on national market. See also pp. 124-135.
² "Depot" preparation for injection.
Table 1 (continued)
Examples of national requirements for equivalence studies\(^1\)

<table>
<thead>
<tr>
<th>Drug substance</th>
<th>Dosage form</th>
<th>Canada</th>
<th>Germany</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>folic acid</td>
<td>tablet, 5 mg, 1 mg</td>
<td>+b</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>tablet, 250 µg + ferrous sulfate, 60 mg Fe</td>
<td>-</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>furosemide</td>
<td>tablet, 40 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>gentamicin sulfate</td>
<td>solution (eye drops), 0.3%</td>
<td>+c</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td>glyceryl trinitrate</td>
<td>tablet (sublingual), 500 µg</td>
<td>?</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>griseofulvin</td>
<td>capsule, 125 mg, 250 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 125 mg, 250 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>haloperidol</td>
<td>tablet, 2 mg, 5 mg</td>
<td>+b</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>hydralazine</td>
<td>tablet, 25 mg, 50 mg</td>
<td>+b</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>hydrochloride</td>
<td>o</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>hydrochlorothiazide</td>
<td>tablet, 25 mg, 50 mg</td>
<td>?</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>hydrocortisone acetate</td>
<td>cream, 1%</td>
<td>o</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>ointment, 1%</td>
<td>o</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>suppository, 25 mg</td>
<td>o</td>
<td>+p+c</td>
<td>?</td>
</tr>
<tr>
<td>ibuprofen</td>
<td>tablet, 200 mg</td>
<td>+b</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>idoxuridine</td>
<td>eye ointment, 0.2%</td>
<td>o</td>
<td>+p+c</td>
<td>+c</td>
</tr>
<tr>
<td></td>
<td>solution (eye drops) 0.1%</td>
<td>o</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>indometacin</td>
<td>capsule, 25 mg</td>
<td>+b</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 25 mg</td>
<td>+b</td>
<td>-</td>
<td>o</td>
</tr>
<tr>
<td>insulin:</td>
<td>injection, 40 IU/ml in 10-ml vial, 80 IU/ml in 10-ml vial, 100 IU/ml in 10-ml vial</td>
<td>+b</td>
<td>-</td>
<td>+b+p</td>
</tr>
<tr>
<td></td>
<td>+b</td>
<td>-</td>
<td>+b+p</td>
<td></td>
</tr>
<tr>
<td></td>
<td>+b</td>
<td>-</td>
<td>+b+p</td>
<td></td>
</tr>
<tr>
<td>insulin zinc suspension</td>
<td>injection, 40 IU of insulin/ml in 10-ml vial</td>
<td>+b</td>
<td>o</td>
<td>+b+p</td>
</tr>
<tr>
<td></td>
<td>80 IU of insulin/ml in 10-ml vial</td>
<td>+b</td>
<td>o</td>
<td>+b+p</td>
</tr>
<tr>
<td>insulin</td>
<td>100 IU of insulin/ml in 10-ml vial</td>
<td>+b</td>
<td>-</td>
<td>+b+p</td>
</tr>
<tr>
<td>(intermediate-acting)</td>
<td>injection, 40 IU of insulin/ml in 10-ml vial</td>
<td>+b</td>
<td>+b</td>
<td>+b+p</td>
</tr>
<tr>
<td></td>
<td>80 IU of insulin/ml in 10-ml vial</td>
<td>+b</td>
<td>+b</td>
<td>+b+p</td>
</tr>
<tr>
<td></td>
<td>100 IU of insulin/ml in 10-ml vial</td>
<td>+b</td>
<td>+b</td>
<td>+b+p</td>
</tr>
</tbody>
</table>

\(^1\): in vivo studies required; +b: bioequivalence studies; +p: pharmacodynamic studies; +c: clinical trials; −: no in vivo studies required; ?: decision on the type of in vivo studies pending; o: no information available, no final decision taken, or not available on national market. See also pp. 124-135.
<table>
<thead>
<tr>
<th>Drug substance</th>
<th>Dosage form</th>
<th>Canada</th>
<th>Germany</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Iodized oil</td>
<td>capsule, 200 mg</td>
<td>?</td>
<td>o</td>
<td>o</td>
</tr>
<tr>
<td>Iopanoic acid</td>
<td>tablet, 500 mg</td>
<td>o</td>
<td>o</td>
<td>-</td>
</tr>
<tr>
<td>Iron dextran</td>
<td>injection, 50 mg of Fe/ml in 2-ml ampoule</td>
<td>+c</td>
<td>-</td>
<td>+b+p</td>
</tr>
<tr>
<td>Isoniazid</td>
<td>tablet, 100–300 mg</td>
<td>+b</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>tablet, 100 mg + rifampicin, 150 mg</td>
<td>o</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>130 mg + rifampicin, 300 mg</td>
<td>o</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 100 mg + thioacetazone, 50 mg</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td>300 mg + thioacetazone, 150 mg</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>Isonitrite dinitrate</td>
<td>tablet (sublingual), 5 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>Ivermectin</td>
<td>scored tablet, 6 mg</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>Ketoconazole</td>
<td>oral suspension, 100 mg/5 ml</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 200 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>Levamisole</td>
<td>tablet, 50 mg, 150 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>Hydrochloride</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levodopa</td>
<td>tablet, 100 mg + carbidopa, 10 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>250 mg + carbidopa, 25 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>Levonorgestrel</td>
<td>tablet, 150 µg + ethinylestradiol, 30 µg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>Levothyroxine sodium</td>
<td>tablet, 50 µg, 100 µg</td>
<td>?</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>Lithium carbonate</td>
<td>capsule, 300 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 300 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>Mebendazole</td>
<td>chewable tablet, 100 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b+c</td>
</tr>
<tr>
<td>Medroxyprogesterone acetate (depot)</td>
<td>injection, 150 mg/ml in 1-ml vial, 50 mg/ml in 3-ml vial</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>Mefloquine</td>
<td>tablet, 250 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>Hydrochloride</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mercaptopurine</td>
<td>tablet, 50 mg</td>
<td>-c+b</td>
<td>+b</td>
<td>+b</td>
</tr>
</tbody>
</table>

1: +: in vivo studies required; +b: bioequivalence studies; +p: pharmacodynamic studies; -c: clinical trials; -: no in vivo studies required; ?: decision on the type of in vivo studies pending; o: no information available, no final decision taken, or not available on national market. See also pp. 124-135.
<table>
<thead>
<tr>
<th>Drug substance</th>
<th>Dosage form</th>
<th>Canada</th>
<th>Germany</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>methionine (DL-)</td>
<td>tablet, 250 mg</td>
<td>?</td>
<td>?</td>
<td>-</td>
</tr>
<tr>
<td>methotrexate sodium</td>
<td>tablet, 2.5 mg of methotrexate</td>
<td>+b+c</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>methyldopa</td>
<td>tablet, 250 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>metoclopramide hydrochloride</td>
<td>tablet, 10 mg of metoclopramide</td>
<td>+b</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>metrifonate</td>
<td>tablet, 100 mg</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>metronidazole</td>
<td>suppository, 500 mg, 1 g</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td>tablet, 200-500 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>metronidazole/benzoate</td>
<td>oral suspension, 200 mg of metronidazole/5 ml</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>mexenone</td>
<td>cream</td>
<td>o</td>
<td>+p+c</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td>lotion</td>
<td>o</td>
<td>+p+c</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td>gel</td>
<td>o</td>
<td>+p+c</td>
<td>o</td>
</tr>
<tr>
<td>miconazole nitrate</td>
<td>cream, 2%</td>
<td>+c</td>
<td>+p+c</td>
<td>+c</td>
</tr>
<tr>
<td></td>
<td>ointment, 2%</td>
<td>+c</td>
<td>+p+c</td>
<td>+c</td>
</tr>
<tr>
<td>morphine sulfate</td>
<td>tablet, 10 mg</td>
<td>o</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>nalidixic acid</td>
<td>tablet, 500 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>neomycin sulfate</td>
<td>ointment, 5 mg + bacitracin zinc, 500 IU/g</td>
<td>o</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td>neostigmine bromide</td>
<td>tablet, 15 mg</td>
<td>?</td>
<td>?</td>
<td>-</td>
</tr>
<tr>
<td>nicosamide</td>
<td>chewable tablet, 500 mg</td>
<td>o</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>nicotinamide</td>
<td>tablet, 50 mg</td>
<td>-</td>
<td>?</td>
<td>-</td>
</tr>
<tr>
<td>nitrofurantoin</td>
<td>capsule, 10 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 10 mg</td>
<td>+b</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>nitrofurantoin</td>
<td>tablet, 30 mg, 120 mg, 250 mg</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>norethisterone</td>
<td>tablet, 100 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>norethisterone enenate</td>
<td>tablet, 350 μg, 5 mg</td>
<td>+b</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td>tablet, 1.0 mg + ethinylestradiol, 35 μg</td>
<td>+b</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>norethisterone enenate oily solution, 200 mg/ml in 1-ml ampoule</td>
<td>?</td>
<td>+b</td>
<td>o</td>
<td></td>
</tr>
<tr>
<td>nystatin</td>
<td>lozenge, 100,000 IU</td>
<td>+</td>
<td>?</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 100,000 IU, 500,000 IU</td>
<td>o</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

1: +: in vivo studies required; +b: bioequivalence studies; +p: pharmacodynamic studies; +c: clinical trials; -: no in vivo studies required; ?: decision on the type of in vivo studies pending; o: no information available, no final decision taken, or not available on national market. See also pp. 124–135.
### Table 1 (continued)

**Examples of national requirements for equivalence studies**

<table>
<thead>
<tr>
<th>Drug substance</th>
<th>Dosage form</th>
<th>Canada</th>
<th>Germany</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>oxamnique</td>
<td>capsule, 250 mg</td>
<td>o</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>oxybenzone</td>
<td>cream</td>
<td>-</td>
<td>+p+c</td>
<td>+c</td>
</tr>
<tr>
<td></td>
<td>gel</td>
<td>-</td>
<td>+p+c</td>
<td>+c</td>
</tr>
<tr>
<td></td>
<td>lotion</td>
<td>-</td>
<td>+p+c</td>
<td>+c</td>
</tr>
<tr>
<td>paracetamol</td>
<td>suppository, 100 mg</td>
<td>+b</td>
<td>-</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td>tablet, 100−500 mg</td>
<td>-</td>
<td>-</td>
<td>o</td>
</tr>
<tr>
<td>penicillamine</td>
<td>capsule, 250 mg</td>
<td>+b</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 250 mg</td>
<td>+b</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>permethrin</td>
<td>lotion, 1%</td>
<td>-</td>
<td>+p+c</td>
<td>+c</td>
</tr>
<tr>
<td>pethidine hydrochloride</td>
<td>tablet, 50 mg, 100 mg</td>
<td>o</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>phenobarbital</td>
<td>tablet, 15−100 mg</td>
<td>-</td>
<td>o</td>
<td>-</td>
</tr>
<tr>
<td>phenoxymethylpenicillin potassium</td>
<td>powder for oral suspension, 250 mg of phenoxymethylpenicillin/5 ml</td>
<td>o</td>
<td>-b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 250 mg of phenoxymethylpenicillin</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>phenytoin sodium</td>
<td>capsule, 25 mg, 100 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 25 mg, 100 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>phytomenadione</td>
<td>tablet, 10 mg</td>
<td>+b</td>
<td>o</td>
<td>+b</td>
</tr>
<tr>
<td>pilocarpine hydrochloride</td>
<td>solution (eye drops), 2%, 4%</td>
<td>o</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td>pilocarpine nitrate</td>
<td>solution (eye drops), 2%, 4%</td>
<td>o</td>
<td>+p+c</td>
<td>o</td>
</tr>
<tr>
<td>piperazine adipate</td>
<td>tablet, 500 mg of piperazine hydrate</td>
<td>-</td>
<td>o</td>
<td>o</td>
</tr>
<tr>
<td>piperazine citrate</td>
<td>tablet, 500 mg of piperazine hydrate</td>
<td>-</td>
<td>o</td>
<td>+b</td>
</tr>
<tr>
<td>podophyllin resin</td>
<td>solution, topical, 10−25%</td>
<td>o</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td>potassium iodide</td>
<td>tablet, 60 mg</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>praziquantel</td>
<td>tablet, 150 mg, 600 mg</td>
<td>o</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>prednisolone</td>
<td>solution (eye drops), 0.5%</td>
<td>o</td>
<td>+p+c</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td>tablet, 1 mg, 5 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>primaquine diphosphate</td>
<td>tablet, 7.5 mg of primaquine, 15 mg of primaquine</td>
<td>?</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>procainamide hydrochloride</td>
<td>tablet, 250 mg, 500 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
</tbody>
</table>

1: +: in vivo studies required; +b: bioequivalence studies; +p: pharmacodynamic studies; +c: clinical trials; -: no in vivo studies required; ?: decision on the type of in vivo studies pending; o: no information available, no final decision taken, or not available on national market. See also pp. 124−135.
Table 1 (continued)

Examples of national requirements for equivalence studies\(^1\)

<table>
<thead>
<tr>
<th>Drug substance</th>
<th>Dosage form</th>
<th>Canada</th>
<th>Germany</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>procaine benzylpenicillin</td>
<td>powder for injection, 1 g (= 1 million IU), 3 g (= 3 million IU)</td>
<td>?</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>procarbazine hydrochloride</td>
<td>capsule, 50 mg</td>
<td>+c+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>promethazine hydrochloride</td>
<td>tablet, 100 mg</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>propranolol hydrochloride</td>
<td>tablet, 10 mg, 25 mg, 40 mg, 80 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>propylidone</td>
<td>oily suspension, 500-600 mg/ml in 20-ml ampoule</td>
<td>o</td>
<td>o</td>
<td>-</td>
</tr>
<tr>
<td>propylthiouracil</td>
<td>tablet, 50 mg</td>
<td>?</td>
<td>-</td>
<td>+b</td>
</tr>
<tr>
<td>pyrantel embonate</td>
<td>oral suspension, 50 mg of pyrantel/ml chewing tablet, 250 mg of pyrantel</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>pyrazinamide</td>
<td>tablet, 500 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>pyridostigmine bromide</td>
<td>tablet, 60 mg</td>
<td>+b</td>
<td>?</td>
<td>+b</td>
</tr>
<tr>
<td>pyridoxine hydrochloride</td>
<td>tablet, 25 mg</td>
<td>-</td>
<td>?</td>
<td>-</td>
</tr>
<tr>
<td>pyrimethamine</td>
<td>tablet, 25 mg + sulfadoxine, sulfadoxine, 500 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>quinidine sulfate</td>
<td>tablet, 200 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>quinine bisulfate</td>
<td>tablet, 300 mg of quinine</td>
<td>+b</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>quinine sulfate</td>
<td>tablet, 300 mg of quinine</td>
<td>?</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>reserpine</td>
<td>tablet, 100 µg, 250 µg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>retinol palmitate</td>
<td>capsule, 200,000 IU, 100,000 IU of retinol sugar-coated tablet, 10,000 IU of retinol</td>
<td>-</td>
<td>?</td>
<td>o</td>
</tr>
<tr>
<td>riboflavin</td>
<td>tablet, 5 mg</td>
<td>-</td>
<td>?</td>
<td>-</td>
</tr>
</tbody>
</table>

1\(^1\): in vivo studies required; +b: bioequivalence studies; +p: pharmacodynamic studies; +c: clinical trials; -: no in vivo studies required; ?: decision on the type of in vivo studies pending; o: no information available, no final decision taken, or not available on national market. See also pp. 124-135.
<table>
<thead>
<tr>
<th>Drug substance</th>
<th>Dosage form</th>
<th>Canada</th>
<th>Germany</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>rifampicin</td>
<td>capsule, 150 mg, 300 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 150 mg, 300 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 150 mg + isoniazid, 100 mg</td>
<td>o</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>300 mg + isoniazid, 150 mg</td>
<td>o</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>salbutamol sulfate</td>
<td>inhalation (aerosol), 100 µg</td>
<td>+p</td>
<td>+p+c</td>
<td>+p</td>
</tr>
<tr>
<td></td>
<td>of salbutamol per dose</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>respirator solution for use</td>
<td>+p</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>in nebulizers, 5 mg/ml</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>tablet, 2 mg, 4 mg of salbutamol</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>salicylic acid</td>
<td>cream, 3% + benzoic acid, 6%</td>
<td>-</td>
<td>+p+c</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td>ointment, 3% + benzoic acid, 6%</td>
<td>-</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>solution, topical, 5%</td>
<td>-</td>
<td>+p+c</td>
<td>o</td>
</tr>
<tr>
<td>silver nitrate</td>
<td>solution (eye drops), 1%</td>
<td>o</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td>silver sulfadiazine</td>
<td>cream, 1% in 500-g container</td>
<td>+c</td>
<td>+p+c</td>
<td>+c</td>
</tr>
<tr>
<td>sodium cromoglicate</td>
<td>inhalation, 20 mg/dose</td>
<td>+c</td>
<td>+p+c</td>
<td>+p+c</td>
</tr>
<tr>
<td>sodium fluoride</td>
<td>tablet, 500 µg</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>sodium valproate</td>
<td>enteric coated tablet, 200 mg, 500 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>spironolactone</td>
<td>tablet, 25 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>sulfadimidine</td>
<td>tablet, 500 mg</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>sulfadoxine</td>
<td>tablet, 500 mg + pyrimethamine, 25 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>sulfamethoxazole</td>
<td>oral suspension 200 mg + trimethoprim, 40 mg/5 ml</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 100 mg + trimethoprim, 20 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>400 mg + trimethoprim, 80 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>sulfasalazine</td>
<td>tablet, 500 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>tamoxifen citrate</td>
<td>tablet, 10 mg of tamoxifen, 20 mg of tamoxifen</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>testosterone enantate</td>
<td>injection, 200 mg in 1-ml ampoule</td>
<td>?</td>
<td>+b</td>
<td>-</td>
</tr>
<tr>
<td>tetracaine hydrochloride</td>
<td>solution (eye drops), 0.5%</td>
<td>o</td>
<td>+p+c</td>
<td>-</td>
</tr>
</tbody>
</table>

1: +: in vivo studies required; +b: bioequivalence studies; +p: pharmacodynamic studies; +c: clinical trials; -: no in vivo studies required; ?: decision on the type of in vivo studies pending; o: no information available, no final decision taken. or not available on national market. See also pp. 124-135.
Table 1 (continued)

Examples of national requirements for equivalence studies

<table>
<thead>
<tr>
<th>Drug substance</th>
<th>Dosage form</th>
<th>Canada</th>
<th>Germany</th>
<th>USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>tetracycline hydrochloride</td>
<td>capsule, 250 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 250 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>eye ointment, 1%</td>
<td>?</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td>thiamine hydrochloride</td>
<td>tablet, 50 mg</td>
<td>-</td>
<td>?</td>
<td>-</td>
</tr>
<tr>
<td>thioacetazone</td>
<td>tablet, 50 mg + isoniazid, 100 mg</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td></td>
<td>150 mg + isoniazid, 300 mg</td>
<td>o</td>
<td>+b</td>
<td>o</td>
</tr>
<tr>
<td>tolbutamide</td>
<td>tablet, 500 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>trimethoprim</td>
<td>oral suspension, 40 mg + sulfamethoxazole, 200 mg/5 ml</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>tablet, 100 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>200 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td></td>
<td>80 mg + sulfamethoxazole, 400 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>tropicamide</td>
<td>solution (eye drops), 0.5%</td>
<td>o</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td>verapamil hydrochloride</td>
<td>tablet, 40 mg, 80 mg</td>
<td>+b</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>warfarin sodium</td>
<td>tablet, 1 mg, 2 mg, 5 mg</td>
<td>?</td>
<td>+b</td>
<td>+b</td>
</tr>
<tr>
<td>zinc oxide</td>
<td>cream</td>
<td>-</td>
<td>+p+c</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>ointment</td>
<td>-</td>
<td>+p+c</td>
<td>-</td>
</tr>
</tbody>
</table>

1. +: in vivo studies required; +b: bioequivalence studies; +p: pharmacodynamic studies; +c: clinical trials; -: no in vivo studies required; ?: decision on the type of in vivo studies pending; o: no information available, no final decision taken, or not available on national market. See also pp. 124–135.

Reference

Appendix 2

Explanation of symbols used in the design of bioequivalence studies in humans, and commonly used pharmacokinetic abbreviations

\[ C_{\text{max}} \] The observed maximum or peak concentration of drug (or metabolite) in plasma, serum or whole blood.

\[ C_{\text{min}} \] The minimum plasma concentration.

\[ C_{\text{max-ratio}} \] The ratio of the geometric means of the test and reference \( C_{\text{max}} \) values.

\[ C_{\text{av}} \] The average plasma concentration.

\[ \text{AUC} \] The area under the curve for drug (or metabolite) concentration in plasma (or serum or whole blood) against time. The value of AUC may be that for a specific period, e.g. AUC from zero to 12 hours is shown as AUC\(_{12}\).

\[ \text{AUC}_t \] AUC from zero to the last quantifiable concentration.

\[ \text{AUC}_\infty \] AUC from zero to infinity, obtained by extrapolation.

\[ \text{AUC}_T \] AUC over one dosing interval (\( T \)) under steady-state conditions.

\[ \text{AUC-ratio} \] The ratio of the geometric means of the test and reference AUC values.

\[ Ae \] The cumulative urinary recovery of parent drug (or metabolite). The value of \( Ae \) may be that for a specific period, e.g. \( Ae \) from zero to 12 hours is shown as \( Ae_{12} \).

\[ Ae_t \] \( Ae \) from zero to the last quantifiable concentration.

\[ Ae_\infty \] \( Ae \) from zero to infinite time, obtained by extrapolation.

\[ Ae_T \] \( Ae \) over one dosing interval under steady-state conditions.

\[ \text{d}Ae/\text{d}t \] The rate of urinary excretion of parent drug (or metabolite).

\[ t_{\text{max}} \] The time after administration of the drug at which \( C_{\text{max}} \) is observed.

\[ t_{\text{max-diff}} \] The difference between the arithmetic means of the test and reference \( t_{\text{max}} \) values.

\[ t_{1/2} \] The plasma (serum, whole blood) half-life.

\[ \text{MRT} \] The mean residence time.

\[ \mu_T \] Average bioavailability of the test product.

\[ \mu_R \] Average bioavailability of the reference product.
Appendix 3

Technical aspects of bioequivalence statistics

The pharmacokinetic characteristics to be tested, the test procedure and the norms to be maintained should be specified beforehand in the protocol. A post hoc change in the methods specified for the statistical evaluation is acceptable only if adherence to the protocol would preclude a meaningful evaluation and if such a change in procedure has been fully justified.

Concentration-dependent data such as AUC and $C_{\text{max}}$ should be log transformed before statistical analysis in order to satisfy the fundamental assumption underlying analysis of variance that effects in the model act in an additive rather than a multiplicative manner.

Acceptance ranges for main characteristics

AUC-ratio
The 90% confidence interval for this measure of relative bioavailability should lie within a bioequivalence range of 80–125% (see p. 131). If the therapeutic range is particularly narrow, the acceptance range may need to be reduced. A larger acceptance range may be acceptable if clinically appropriate.

$C_{\text{max}}$-ratio
This measure of relative bioavailability is inherently more variable than, for example, the AUC-ratio, and a wider acceptance range may be appropriate. The range used should be justified, taking into account safety and efficacy considerations.

$t_{\text{max}}$-diff
Statistical evaluation of $t_{\text{max}}$ makes sense only if there is a clinically relevant claim for rapid release or action, or signs of a relation to adverse effects. The non-parametric 90% confidence interval for this measure of relative bioavailability should lie within a clinically relevant range.
Annex 10
Guidelines for implementation of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce

1. Provisions and objectives

1.1 A comprehensive system of quality assurance must be founded on a reliable system of licensing\(^1\) and independent analysis of the finished product, as well as on an assurance obtained through independent inspection that all manufacturing operations are carried out in conformity with accepted norms referred to as “good manufacturing practices” (GMP).

1.2 In 1969, the Twenty-second World Health Assembly, by resolution WHA22.50, endorsed requirements for “Good practices in the manufacture and quality control of drugs”\(1\) (referred to henceforth as “GMP as recommended by WHO”). These comprise internationally recognized and respected standards that all Member States are urged to adopt and to apply. These requirements have since been revised twice. The first revision was adopted by the Health Assembly in 1975 in

---

\(^1\) Throughout this document licensing refers to any statutory system of approval required at national level as a precondition for placing a pharmaceutical product on the market.
resolution WHA28.65 (2), and a second revision of the requirements is included in the thirty-second report of the WHO Expert Committee on Specifications for Pharmaceutical Preparations (3).

1.3 These standards are fully consonant with those operative within the countries participating in the Convention for the Mutual Recognition of Inspection in Respect of the Manufacture of Pharmaceutical Products, and other major industrialized countries. They also provide the basis for the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce (referred to henceforth as “the Scheme”) recommended initially in resolution WHA22.50 (7). The Scheme is an administrative instrument that requires each participating Member State, upon application by a commercially interested party, to attest to the competent authority of another participating Member State that:

- a specific product is authorized to be placed on the market within its jurisdiction or, if it is not thus authorized, the reason why that authorization has not been accorded;
- the plant in which it is produced is subject to inspections at suitable intervals to establish that the manufacturer conforms to GMP as recommended by WHO; and
- all submitted product information, including labelling, is currently authorized in the certifying country.

1.4 The Scheme, as subsequently amended in 1975 (2) and 1988 (4) by resolutions WHA28.65 and WHA41.18, is applicable to finished dosage forms of pharmaceutical products intended for administration to human beings or to food-producing animals.

1.5 Provision for the certification of active ingredients is also included within the scope of the Scheme. This will be the subject of separate guidelines and certificates.

2. **Eligibility for participation**

2.1 Any Member State intending to participate in the Scheme may do so by notifying the Director-General of WHO, in writing, of:

- its willingness to participate in the Scheme;
- any significant reservations it intends to observe relating to this participation; and
- the name and address of its national drug authority or other competent authority.

2.2 These notifications are subsequently announced in the monthly WHO pharmaceuticals newsletter. An updated consolidated list will be published annually in the newsletter and will be available to governments at other times from the Division of Drug Management and Policies, WHO, 1211 Geneva 27, Switzerland. (See also section 3.3).
2.3 A Member State may opt to participate solely to control the import of pharmaceutical products and active substances. This intention should be stated explicitly in its notification to WHO.

2.4 A Member State intending to use the Scheme to support the export of pharmaceutical products should first satisfy itself that it possesses:

- An effective national licensing system, not only for pharmaceutical products, but also for the responsible manufacturers and distributors.
- GMP requirements, consonant with those recommended by WHO, to which all manufacturers of finished pharmaceutical products are required to conform.
- Effective controls to monitor the quality of pharmaceutical products registered or manufactured within the country, including access to an independent quality control laboratory.
- A national pharmaceuticals inspectorate, operating as an arm of the national drug regulatory authority, and having the technical competence, experience and resources to assess whether GMP and other controls are being effectively implemented, and the legal power to conduct appropriate investigations to ensure that manufacturers conform to these requirements by, for example, examining premises and records and taking samples.
- The administrative capacity to issue the required certificates, to institute inquiries in the case of complaint, and to notify expeditiously both WHO and the competent authority in any Member State known to have imported a specific product that is subsequently associated with a potentially serious quality defect or other hazard.

2.5 Each Member State assumes the responsibility to determine, through a process of self-evaluation, whether it satisfies these prerequisites. The Scheme contains no provision for external inspection or assessment under any circumstances, either of a competent national authority or of a manufacturing facility. However, should a Member State so wish, it can approach WHO, or a well recognized drug regulatory authority, occasionally to delegate consultants to act as advisers in the course of both national inspections and inspector training activities.

3. Requesting a certificate

3.1 Three documents can be requested within the scope of the Scheme:
- a Certificate of Pharmaceutical Product (product certificate);
- a Statement of Licensing Status of Pharmaceutical Product(s); and
- a Batch Certificate of a Pharmaceutical Product.

3.2 Proposed formats for these documents are provided in Appendices 1, 2 and 3 of these guidelines. To facilitate their use, they are presented in forms suitable for generation by computer. All participating countries are henceforth urged to adopt these formats to facilitate the interpretation of certified information. Requests for the provision of certificates offering
more limited attestations – for instance, that the manufacturer complies with GMP or that the product is authorized for “free sale” within the country of export – are discouraged. Similarly, requests should not be made for the certification of information going beyond the scope of the Scheme. When manufacture takes place in a country other than that where the product certificate is issued, an attestation that such manufacture complies with GMP may still be provided as an attachment to the product certificate on the basis of inspections undertaken for registration purposes. The explanatory notes attached to the three documents referred to above are very important. While they are not part of the documents, they should always be attached to them.

3.3 A list of addresses of competent national regulatory authorities participating in the Scheme that are responsible for the registration of pharmaceutical and/or veterinary products, together with details of any reservations they have declared regarding their participation in the Scheme may be obtained from WHO as indicated in section 2.2.

3.4 The competent authority in each country participating in the Scheme should issue guidelines to all agents responsible for importing pharmaceutical products for human and/or veterinary use that operate under its jurisdiction, including those responsible for public sector purchases, to explain the contribution of certification of the drug regulatory process and the circumstances in which each of the three types of documents will be required.

**Certificate of a Pharmaceutical Product**

3.5 The Certificate of a Pharmaceutical Product (Appendix 1), issued by the exporting country, is intended for use by the competent authority within an importing country in two situations:

- when the product in question is under consideration for a product licence that will authorize its importation and sale;
- when administrative action is required to renew, extend, vary or review such a licence.

3.6 All requests for certificates should be channelled through the agent in the importing country (see section 3.4) and the product-licence holder or other commercially interested party in the exporting country (“the applicant”). The applicant should submit the following information for each product to the authority issuing the certificate:

- the name and dosage form of the product;
- the name and the amount of active ingredient(s) per unit dose (the International Nonproprietary Name(s), where such exist(s), should be used);
- the name and address of the product-licence holder and/or manufacturing facility;
— the formula (the complete qualitative composition including all excipients); this is particularly important when no product licence exists or when the formulation differs from that of the licensed product;
— product information for health professionals and for the public (patient information leaflets) as approved in the exporting country.

For product information to be attached to the certificate, see section 4.7.

3.7 The certificate is a confidential document. As such, it can be issued by the competent authority in the exporting country ("the certifying authority") only with the permission of the applicant and, if different, of the product-licence holder.

3.8 The certificate is intended to be incorporated into a product-licence application in the importing country. Once prepared, it is transmitted to the requesting authority through the applicant and, when applicable, the agent in the importing country.

3.9 When any doubt arises about the status or validity of a certificate, the competent authority in the importing country should request a copy directly from the certifying authority, as provided for in section 4.9 of these guidelines.

3.10 In the absence of any specific agreement, each certificate will be prepared exclusively in the working language(s) of the certifying authority. The applicant will be responsible for providing any notarized translation that may be required by the requesting authority.

3.11 Since the preparation of certificates imposes a significant administrative load on certifying authorities, the service may need to be financed by charges levied upon applicants.

3.12 Supplementary attestations are obtainable only at the discretion of the certifying authority and with the permission of the applicant. The certifying authority is under no obligation to supply additional information. Requests for supplementary information should consequently be referred to the applicant, and only in exceptional circumstances to the certifying authority.

**Statement of Licensing Status**

3.13 The Statement of Licensing Status of Pharmaceutical Product(s) (Appendix 2) attests only that a licence has been issued for a specified product, or products, for use in the exporting country. It is intended for use by importing agents when considering bids made in response to an international tender, in which case it should be requested by the agent as a condition of bidding. It is intended only to facilitate the screening and preparation of information. The importation of any product that is provisionally selected through this procedure should be determined on the basis of a Certificate of a Pharmaceutical Product.
**Batch Certificate**

3.14 A Batch Certificate of a Pharmaceutical Product (Appendix 3) refers to an individual batch of a pharmaceutical product, and is a vital instrument in drug procurement. The provision of a Batch Certificate is usually a mandatory requirement in tender and procurement documents.

3.15 A Batch Certificate is normally issued by the manufacturer and only *exceptionally*, as in the case of vaccines, sera and some other biological products, by the competent authority of the exporting country. The Batch Certificate is intended to accompany and provide an attestation concerning the quality and expiry date of a specific batch or consignment of a product that has already been licensed in the importing country. The Batch Certificate should include the specifications of the final product at the time of batch release and the results of a full analysis undertaken on the batch in question. In most circumstances these certificates are issued by the manufacturer to the importing agent (i.e. the product-licence holder in the importing country), but they must be made available at the request of – or in the course of any inspection made on behalf of – the competent national authority.

4. **Issuing a certificate**

4.1 The certifying authority is responsible for assuring the authenticity of the certified data. Certificates should not bear the WHO emblem, but a statement should always be included to confirm whether or not the document is issued in the format recommended by WHO.

4.2 When the applicant is the manufacturer of the finished dosage form, the certifying authority should satisfy itself, before attesting compliance with GMP, that the applicant:

(a) applies identical GMP standards to the production of all batches of pharmaceutical products manufactured within the facility, *including those destined exclusively for export*;

(b) consents, in the event of identification of a quality defect consonant with the criteria set out in section 5.1, to relevant inspection reports being released, in confidence, to the competent authority in the country of import, should the latter so require.

4.3 When the applicant is not the manufacturer of the finished dosage form, the certifying authority should similarly satisfy itself – in so far as it has authority to inspect the records and relevant activities of the applicant – that it has the applicant’s consent to release relevant reports on the same basis as described in section 4.2 (b) above.

4.4 GMP as recommended by WHO assigns to the manufacturer of the finished dosage form responsibility for assuring the quality of active ingredients. National regulations may require that suppliers of active ingredients be identified in the product licence, but the competent authority may have no power to inspect them.
4.5 Notwithstanding this situation, a certifying authority may agree, on a discretionary and voluntary basis, and at the request of a manufacturer, to undertake an inspection of a manufacturer of active ingredients to satisfy specific requirements of a requesting authority. Alternatively, pending the development of specific guidelines for active pharmaceutical ingredients, the certifying authority may be able to attest that the manufacturer is an established supplier of the substance in question to manufacturers of finished dosage forms licensed for marketing under its jurisdiction.

4.6 Whenever a product is purchased through a broker or another intermediary, or when more than one set of premises has been involved in the manufacture and packaging of a product, the certifying authority should consider whether it has received sufficient information to satisfy itself that those aspects of the manufacture of the product for which the applicant is not directly responsible have been undertaken in compliance with GMP as recommended by WHO.

4.7 The certifying authority should officially stamp and date all copies of product information submitted to it in support of an application for a certificate and intended to be appended to the certificate. Every effort should be made to ensure that certificates and all annexed documentation are consonant with the version of the product licence operative on the date of issue. When available, the certifying authority will add a summary basis of approval or any other material that it may deem relevant. Translation by an applicant of these materials into a widely used language, preferably English, shall be deemed to satisfy the provisions of section 3.10.

4.8 Any additional attachment to a certificate submitted by the applicant, such as price lists of products for which bids are offered, should be clearly identified as not forming part of the attestation made by the certifying authority.

4.9 To avert potential abuse of the Scheme, to frustrate attempts at falsification, to render routine authentication of certificates by an independent authority superfluous, and to enable the certifying authority to maintain comprehensive records of countries to which specific products have been exported, each certificate should identify the importing country and be stamped on each page with the official seal of the certifying authority. If requested by the importing country, an identical copy, clearly marked as duplicate, should be forwarded by the certifying authority directly to that country’s authority.

5. **Notifying and investigating a quality defect**

5.1 Each certifying authority undertakes to institute enquiries into any quality defect reported in a product exported in accordance with the provisions of the Scheme, on the understanding that:

- the complaint is transmitted, together with the relevant facts, through the competent authority in the importing country;
- the complaint is considered to be of a serious nature by the latter authority; and
- the defect, if it appeared after delivery of the product into the importing country, is not attributable to local conditions.

5.2 In the case of obvious doubt, a participating national authority may request WHO to assist in identifying an independent quality control laboratory to carry out tests for the purposes of quality control.

5.3 Each certifying authority undertakes to inform WHO and, as far as is possible, all competent national authorities, of any serious hazard newly associated with a product exported under the provisions of the Scheme or of any criminal abuse of the Scheme directed, in particular, to the export of falsely labelled, spurious, counterfeit or substandard pharmaceutical products. On receipt of such notification, WHO will transmit the message immediately to the competent national authority in each Member State.

5.4 WHO stands prepared to offer advice should difficulty arise in implementing any aspect of the Scheme or in resolving a complaint, but it cannot be a party to any resulting litigation or arbitration.

References


Appendix 1

Model Certificate of a Pharmaceutical Product

Certificate of a Pharmaceutical Product

This certificate conforms to the format recommended by the World Health Organization (general instructions and explanatory notes attached).

No. of Certificate: ________________________________

Exporting (certifying) country: ________________________________

Importing (requesting) country: ________________________________

1. Name and dosage form of product: ________________________________

1.1 Active ingredient(s) and amount(s) per unit dose: ________________________________

For complete qualitative composition including excipients, see attached.

1.2 Is this product licensed to be placed on the market for use in the exporting country? yes/no (key in as appropriate)

1.3 Is this product actually on the market in the exporting country? yes/no/unknown (key in as appropriate)

If the answer to 1.2 is yes, continue with section 2A and omit section 2B.

If the answer to 1.2 is no, omit section 2A and continue with section 2B.

2A.1 Number of product licence and date of issue: ________________________________

2A.2 Product-licence holder (name and address): ________________________________

2A.3 Status of product-licence holder: a/b/c (key in appropriate category as defined in note 8)
2A.3.1 For categories b and c the name and address of the manufacturer producing the dosage form are.\textsuperscript{9}

2A.4 Is Summary Basis of Approval appended?\textsuperscript{10} yes/no (\textit{key in as appropriate})

2A.5 Is the attached, officially approved product information complete and consonant with the licence?\textsuperscript{11} yes/no/not provided (\textit{key in as appropriate})

2A.6 Applicant for certificate, if different from licence holder (name and address).\textsuperscript{12}

2B.1 Applicant for certificate (name and address):

2B.2 Status of applicant: a/b/c (\textit{key in appropriate category as defined in note 8})

2B.2.1 For categories b and c the name and address of the manufacturer producing the dosage form are.\textsuperscript{9}

2B.3 Why is marketing authorization lacking?

not required/not requested/under consideration/refused (\textit{key in as appropriate})

2B.4 Remarks:\textsuperscript{13} 

3. Does the certifying authority arrange for periodic inspection of the manufacturing plant in which the dosage form is produced? yes/no/not applicable\textsuperscript{14} (\textit{key in as appropriate})

If no or not applicable proceed to question 4.

3.1 Periodicity of routine inspections (years): 

164
3.2 Has the manufacture of this type of dosage form been inspected? yes/no  (*key in as appropriate*)

3.3 Do the facilities and operations conform to GMP as recommended by the World Health Organization?*15 yes/no/not applicable*14  (*key in as appropriate*)

4. Does the information submitted by the applicant satisfy the certifying authority on all aspects of the manufacture of the product?*16 yes/no  (*key in as appropriate*)

If no, explain: __________________________________________________________

Address of certifying authority:

__________________________________________________________

Telephone number: __________ Fax number: ______________

Name of authorized person:

__________________________________________________________

Signature:

__________________________________________________________

Stamp and date: ____________________________________________

**General instructions**

Please refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.

The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than handwritten.

Additional sheets should be appended, as necessary, to accommodate remarks and explanations.
Explanatory notes

1 This certificate, which is in the format recommended by WHO, establishes the status of the pharmaceutical product and of the applicant for the certificate in the exporting country. It is for a single product only since manufacturing arrangements and approved information for different dosage forms and different strengths can vary.

2 Use, whenever possible, International Nonproprietary Names (INNs) or national nonproprietary names.

3 The formula (complete composition) of the dosage form should be given on the certificate or be appended.

4 Details of quantitative composition are preferred, but their provision is subject to the agreement of the product-licence holder.

5 When applicable, append details of any restriction applied to the sale, distribution or administration of the product that is specified in the product licence.

6 Sections 2A and 2B are mutually exclusive.

7 Indicate, when applicable, if the licence is provisional, or the product has not yet been approved.

8 Specify whether the person responsible for placing the product on the market:
   (a) manufactures the dosage form;
   (b) packages and/or labels a dosage form manufactured by an independent company; or
   (c) is involved in none of the above.

9 This information can be provided only with the consent of the product-licence holder or, in the case of non-registered products, the applicant. Non-completion of this section indicates that the party concerned has not agreed to inclusion of this information.

   It should be noted that information concerning the site of production is part of the product licence. If the production site is changed, the licence must be updated or it will cease to be valid.

10 This refers to the document, prepared by some national regulatory authorities, that summarizes the technical basis on which the product has been licensed.

11 This refers to product information approved by the competent national regulatory authority, such as a Summary of Product Characteristics (SPC).

12 In this circumstance, permission for issuing the certificate is required from the product-licence holder. This permission must be provided to the authority by the applicant.

13 Please indicate the reason that the applicant has provided for not requesting registration:
   (a) the product has been developed exclusively for the treatment of conditions – particularly tropical diseases – not endemic in the country of export;
   (b) the product has been reformulated with a view to improving its stability under tropical conditions;
(c) the product has been reformulated to exclude excipients not approved for use in pharmaceutical products in the country of import;
(d) the product has been reformulated to meet a different maximum dosage limit for an active ingredient;
(e) any other reason, please specify.

14 Not applicable means that the manufacture is taking place in a country other than that issuing the product certificate and inspection is conducted under the aegis of the country of manufacture.

15 The requirements for good practices in the manufacture and quality control of drugs referred to in the certificate are those included in the thirty-second report of the Expert Committee on Specifications for Pharmaceutical Preparations (WHO Technical Report Series, No. 823, 1992, Annex 1). Recommendations specifically applicable to biological products have been formulated by the WHO Expert Committee on Biological Standardization (WHO Technical Report Series, No. 822, 1992, Annex 1).

16 This section is to be completed when the product-licence holder or applicant conforms to status (b) or (c) as described in note 7 above. It is of particular importance when foreign contractors are involved in the manufacture of the product. In these circumstances the applicant should supply the certifying authority with information to identify the contracting parties responsible for each stage of manufacture of the finished dosage form, and the extent and nature of any controls exercised over each of these parties.

The layout for this Model Certificate is available on diskette in WordPerfect from the Division of Drug Management and Policies, World Health Organization, 1211 Geneva 27, Switzerland.
Appendix 2

Model Statement of Licensing Status of Pharmaceutical Product(s)

No. of Statement ________________

Exporting (certifying) country:

Importing (requesting) country:

Statement of Licensing Status of Pharmaceutical Product(s)¹

This statement indicates only whether or not the following products are licensed to be put on the market in the exporting country.

Applicant (name/address):

<table>
<thead>
<tr>
<th>Name of product</th>
<th>Dosage form</th>
<th>Active ingredient(s)² and amount(s) per unit dose</th>
<th>Product-licence no. and date of issue³</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The certifying authority undertakes to provide, at the request of the applicant (or, if different, the product-licence holder), a separate and complete Certificate of a Pharmaceutical Product in the format recommended by WHO, for each of the products listed above.

Address of certifying authority: ____________________________

Name of authorized person: ____________________________

Telephone/fax numbers: ____________________________

Signature: ____________________________

Stamp and date: ____________________________

This statement conforms to the format recommended by the World Health Organization (general instructions and explanatory notes below).
General instructions

Please refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.

The forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than handwritten.

Additional sheets should be appended, as necessary, to accommodate remarks and explanations.

Explanatory notes

1 This statement is intended for use by importing agents who are required to screen bids made in response to an international tender and should be requested by the agent as a condition of bidding. The statement indicates that the listed products are authorized to be placed on the market for use in the exporting country. A Certificate of a Pharmaceutical Product in the format recommended by WHO will be provided, at the request of the applicant and, if different, the product-licence holder, for each of the listed products.

2 Use, whenever possible, International Nonproprietary Names (INNs) or national nonproprietary names.

3 If no product licence has been granted, enter "not required", "not requested", "under consideration" or "refused" as appropriate.

The layout for this Model Statement is available on diskette in WordPerfect from the Division of Drug Management and Policies, World Health Organization, 1211 Geneva 27, Switzerland.
Appendix 3

Model Batch Certificate of a Pharmaceutical Product

Manufacturer's/Official1 Batch Certificate of a Pharmaceutical Product

This certificate conforms to the format recommended by the World Health Organization (general instructions and explanatory notes attached).

1. No. of Certificate: 

2. Importing (requesting) authority: 

3. Name of product: 

3.1 Dosage form: 

3.2 Active ingredient(s)² and amount(s) per unit dose: 

3.2.1 Is the composition of the product identical to that registered in the country of export? yes/no/not applicable³ (key in as appropriate)

If no, please attach formula (including excipients) of both products.

4. Product-licence holder⁴ (name and address):

4.1 Product-licence number:⁴ 

4.2 Date of issue:⁴ 

4.3 Product licence issued by:⁴ 

4.4 Product-certificate number :⁴,⁵ 

5.1 Batch number: 

5.2 Date of manufacture: 

5.3 Shelf-life (years): 

5.4 Contents of container: 

5.5 Nature of primary container: 

5.6 Nature of secondary container/wrapping: 

5.7 Specific storage conditions: 

---

170
5.8 Temperature range: ________________________________

6. Remarks:______________________________

7. Quality analysis

7.1 What specifications apply to this dosage form? Either specify the pharmacopoeia or append company specifications.

7.1.1 In the case of a product registered in the exporting country, have the company specifications been accepted by the competent authority? yes/no (key in as appropriate)

7.2 Does the batch comply with all parts of the above specifications? yes/no (key in as appropriate)

7.3 Append certificate of analysis.

It is hereby certified that the above declarations are correct and that the results of the analyses and assays on which they are based will be provided on request to the competent authorities in both the importing and the exporting countries.

Name and address of authorized person: ________________________________

Telephone number: _______________ Fax number: _______________

Signature of authorized person: ________________________________

Stamp and date: ________________________________

General instructions

Please refer to the guidelines for full instructions on how to complete this form and information on the implementation of the Scheme.

These forms are suitable for generation by computer. They should always be submitted as hard copy, with responses printed in type rather than handwritten.

Additional sheets should be appended, as necessary, to accommodate remarks and explanations.

Explanatory notes

Certification of individual batches of a pharmaceutical product is only undertaken exceptionally by the competent authority of the exporting country. Even then, it is rarely applied other than to vaccines, sera and biologicals. For other products, the
responsibility for any requirement to provide batch certificates rests with the product-licensure holder in the exporting country. The responsibility to forward certificates to the competent authority in the importing country is most conveniently assigned to the importing agent.

Any inquiries or complaints regarding a batch certificate should always be addressed to the competent authority in the exporting country. A copy should be sent to the product-licensure holder.

1 Strike out whichever does not apply.

2 Use, whenever possible, International Nonproprietary Names (INNs) or national nonproprietary names.

3 "Not applicable" means that the product is not registered in the country of export.

4 All items under 4 refer to the product licence or the Certificate of a Pharmaceutical Product issued in the exporting country.

5 This refers to the Certificate of a Pharmaceutical Product as recommended by the World Health Organization.

6 Indicate any special storage conditions recommended for the product as supplied.

7 For each of the parameters to be measured, the specifications give the values that have been accepted for batch release at the time of product registration.

8 Identify and explain any discrepancies from specifications. Government batch release certificates issued by certain governmental authorities for specific biological products provide additional confirmation that a given batch has been released, without necessarily giving the results of testing. The latter are contained in the manufacturer's certificate of analysis.

The layout for this Model Certificate is available on diskette in WordPerfect from the Division of Drug Management and Policies, World Health Organization, 1211 Geneva 27, Switzerland.
Appendix 4

Glossary and Index

In order to facilitate understanding, terms used in the guidelines are explained here and/or reference is made to relevant sections. This appendix provides supplementary information and is not a formal part of the Scheme.

For the sake of clarity, all definitions taken from the glossary of “Good manufacturing practices for pharmaceutical products” (1) are preceded by an asterisk.

abuse of Scheme
See sections 4.9 and 5.2 of the guidelines.

active ingredients
See sections 1.5, 4.4 and 4.5 of the guidelines.

addresses of competent authorities
See sections 2.2 and 3.3 of the guidelines.

applicant
The party applying for a Product Certificate. This is normally the product-licence holder. Because certain data are confidential for commercial reasons, the competent authority in the exporting country must always obtain permission to release these data from the product-licence holder or, in the absence of a product licence, from the manufacturer.

authentication of certificates
See section 4.9 of the guidelines.

* batch (or lot)
A defined quantity of a starting material, packaging material, or product processed in a single process or series of processes so that it can be expected to be homogeneous. In the case of continuous manufacture, the batch must correspond to a defined fraction of the production, characterized by its intended homogeneity. It may sometimes be necessary to divide a batch into a number of sub-batches, which are later brought together to form a final homogeneous batch.

batch certificate
A document containing information, as set out in Appendix 3 of the guidelines, will normally be issued for each batch by the manufacturer. Furthermore, a batch certificate may exceptionally be validated or issued by the competent authority of the exporting country, particularly for vaccines, sera and other biological products. The batch certificate accompanies every major consignment (see also section 3.14 of the guidelines).
* batch number
A distinctive combination of numbers and/or letters which specifically identifies a batch on the labels, the batch records, and the certificates of analysis, etc.

* bulk product
A product that has completed all processing stages up to, but not including, final packaging.

certifying authority
The competent authority that issues product certificates. It must ensure that it possesses the capacities listed in section 2.4 of the guidelines.

charges for product certificates
See section 3.11 of the guidelines.

competent authority
The national authority as identified in the formal letter of acceptance in which each Member State informs WHO of its intention to participate in the Scheme. The extent of its participation should be indicated in the letter of acceptance (see section 2.1 of the guidelines). The competent authority can issue or receive certificates.

WHO makes available on request a continuously updated list of addresses of competent authorities and, when applicable, the specific conditions for participation.

competence and evaluation of national authority
See sections 2.4, 2.5 and 4.2 of the guidelines.

dosage form
The form of the completed pharmaceutical preparation, e.g. tablet, capsule, elixir, suppository.

drug regulatory authority
An authority appointed by the government of a Member State to administer the granting of marketing authorizations for pharmaceutical products in that country.

* finished product
A product that has undergone all stages of production, including packaging in its final container and labelling.

free sale certificate
See section 3.2 of the guidelines.

GMP certificate
See section 3.2 of the guidelines.
importing agents, guidelines for
See section 3.4 of the guidelines.

language of product certificate
See section 3.10 of the guidelines.

licence holder
An individual or a corporate entity possessing a marketing authorization for a pharmaceutical product.

licensee
An individual or corporate entity responsible for the information and publicity on, and the pharmacovigilance and surveillance of batches of, a pharmaceutical product and, if applicable, for their withdrawal, whether or not that individual or corporate entity is the holder of the marketing authorization.

limits of certificate by competent authority
See sections 3.12 and 4.8 of the guidelines.

lot
See batch.

* manufacture
All operations of purchase of materials and products, production, quality control, release, storage, shipment of finished products, and related controls.

* manufacturer
A company that carries out at least one step of manufacture. (For the different categories of manufacturer, see Appendix 1, explanatory note no. 7.)

marketing authorization
See product licence.

pharmaceutical product
Any medicine intended for human use or administered to food-producing animals, presented in its finished dosage form or as an active ingredient for use in such dosage form, that is subject to control by pharmaceutical legislation in both the exporting state and the importing state.

product
See pharmaceutical product.

product certificate
A document containing the information as set out in Appendix 1 of the guidelines that is validated and issued for a specific product by the competent authority of the exporting country and intended for use by the
competent authority in the importing country or — in the absence of such an authority — by the drug procurement authority (see also section 3.5 of the guidelines).

Transmission of product certificate: see sections 3.8 and 4.9 of the guidelines.

Validity of product certificate: see section 3.9 of the guidelines.

When to request a product certificate: see section 3.5 of the guidelines.

product information
The approved product information referred to in section 4.7 of the guidelines and item 2A.5 of the Product Certificate. It normally consists of information for health professionals and the public (patient information leaflets), as approved in the exporting country and, when available, a data sheet or a Summary of Product Characteristics (SPC) approved by the regulatory authority.

product licence
An official document issued by the competent drug regulatory authority for the purpose of the marketing or free distribution of a product. It must set out, inter alia, the name of the product, the pharmaceutical dosage form, the quantitative formula (including excipients) per unit dose (using International Nonproprietary Names or national generic names, where they exist), the shelf-life and storage conditions, and packaging characteristics. It also contains all the information approved for health professionals and the public (except promotional information), the sales category, the name and address of the licence holder, and the period of validity of the licence.

product-licence holder
See licence holder.

* production
All operations involved in the preparation of a pharmaceutical product, from receipt of materials, through processing and packaging, to completion of the finished product.

registration
Any statutory system of approval required at national level as a precondition for introducing a pharmaceutical product on to the market.

registration certificate
See product licence.

specifications
See Appendix 3, explanatory note 7.
statement of licensing status
See section 3.13 of the guidelines and Appendix 2.

Summary Basis of Approval
The document prepared by some national regulatory authorities that summarizes the technical basis on which the product has been licensed (see section 4.7 of the guidelines and explanatory note 9 of the Product Certificate contained in Appendix 1).

Summary of Product Characteristics (SPC)
Product information as approved by the regulatory authority. The SPC serves as the basis for production of information for health personnel as well as for consumer information on labels and leaflets of medicinal products and for control of advertising (see also Product information).

tenders and brokers
See section 4.6 of the guidelines.

WHO responsibility
See section 5.4 of the guidelines.

Reference
Annex 11
Guidelines for the assessment of herbal medicines\(^1,2\)

Introduction

For the purpose of these guidelines, herbal medicines are defined as follows:

Finished, labelled medicinal products that contain as active ingredients aerial or underground parts of plants, or other plant material, or combinations thereof, whether in the crude state or as plant preparations. Plant material includes juices, gums, fatty oils, essential oils, and any other substances of this nature. Herbal medicines may contain excipients in addition to the active ingredients. Medicines containing plant material combined with chemically defined active substances, including chemically defined, isolated constituents of plants, are not considered to be herbal medicines.

Exceptionally, in some countries herbal medicines may also contain, by tradition, natural organic or inorganic active ingredients which are not of plant origin.

The past decade has seen a significant increase in the use of herbal medicines. As a result of WHO's promotion of traditional medicine, countries have been seeking the assistance of the Organization in identifying safe and effective herbal medicines for use in national health care systems.

In 1991, the Director-General of WHO, in a report to the Forty-fourth World Health Assembly, emphasized the great importance of medicinal plants to the health of individuals and communities. Earlier, in 1978, the Thirty-first World Health Assembly had adopted a resolution (WHA31.33) that called on the Director-General to compile and periodically update a therapeutic classification of medicinal plants, related to the therapeutic classification of all drugs; subsequently, resolution WHA40.33, adopted in 1987, urged Member States to ensure quality control of drugs derived from traditional plant remedies by using

---

\(^1\) Adapted from WHO document WHO/TRM/91.4. These guidelines were finalized at a WHO consultation in Munich, Germany, 19–21 June 1991. The request for WHO to prepare the guidelines came from the Fifth International Conference of Drug Regulatory Authorities (ICDRA) held in Paris in 1989. The finalized guidelines were presented to the Sixth ICDRA in Ottawa in 1991.

\(^2\) Guidelines for the manufacture of herbal medicines are provided in Annex 8.
modern techniques and applying suitable standards and good manufacturing practices; and resolution WHA42.43, of 1989, urged Member States to introduce measures for the regulation and control of medicinal plant products and for the establishment and maintenance of suitable standards. Moreover, the International Conference on Primary Health Care, held in Alma-Ata, USSR, in 1978, recommended, inter alia, the accommodation of proven traditional remedies in national drug policies and regulatory measures.

In developed countries, a resurgence of interest in herbal medicines has resulted from the preference of many consumers for products of natural origin. In addition, manufactured herbal medicines often follow in the wake of migrants from countries where traditional medicines play an important role.

In both developed and developing countries, consumers and health care providers need to be supplied with up-to-date and authoritative information on the beneficial properties, and possible harmful effects, of all herbal medicines.

The Fourth International Conference of Drug Regulatory Authorities, held in Tokyo in 1986, organized a workshop on the regulation of herbal medicines moving in international commerce. Another workshop on the same subject was held as part of the Fifth International Conference of Drug Regulatory Authorities, held in Paris in 1989. Both workshops confined their considerations to the commercial exploitation of traditional medicines through over-the-counter labelled products. The Paris meeting concluded that the World Health Organization should consider preparing model guidelines containing basic elements of legislation designed to assist those countries wishing to develop appropriate legislation and registration.

The objective of these guidelines is to define basic criteria for the evaluation of quality, safety and efficacy of herbal medicines and thereby to assist national regulatory authorities, scientific organizations and manufacturers to undertake an assessment of the documentation/submissions/dossiers in respect of such products. As a general rule in this assessment, traditional experience means that long-term use as well as the medical, historical and ethnological background of those products shall be taken into account. The definition of long-term use may vary according to the country but should be at least several decades. Therefore, the assessment should take into account a description in the medical/pharmaceutical literature or similar sources, or a documentation of knowledge on the application of a herbal medicine without a clearly defined time limitation. Marketing authorizations for similar products should be taken into account.

Prolonged and apparently uneventful use of a substance usually offers testimony of its safety. In a few instances, however, investigation of the potential toxicity of naturally occurring substances widely used as
ingredients in these preparations has revealed previously unsuspected potential for systematic toxicity, carcinogenicity and teratogenicity. Regulatory authorities need to be quickly and reliably informed of these findings. They should also have the authority to respond promptly to such alerts, either by withdrawing or varying the licences of registered products containing suspect substances, or by rescheduling the substances to limit their use to medical prescription.

Assessment of quality

Pharmaceutical assessment

This should cover all important aspects of the quality assessment of herbal medicines. It should be sufficient to make reference to a pharmacopoeial monograph if one exists. If no such monograph is available, a monograph must be supplied and should be set out as in an official pharmacopoeia.

All procedures should be in accordance with good manufacturing practices.

Crude plant material

The botanical definition, including genus, species and authority, should be given to ensure correct identification of a plant. A definition and description of the part of the plant from which the medicine is made (e.g. leaf, flower, root) should be provided, together with an indication of whether fresh, dried or traditionally processed material is used. The active and characteristic constituents should be specified and, if possible, content limits should be defined. Foreign matter, impurities and microbial content should be defined or limited. Voucher specimens, representing each lot of plant material processed, should be authenticated by a qualified botanist and should be stored for at least a 10-year period. A lot number should be assigned and this should appear on the product label.

Plant preparations

Plant preparations include comminuted or powdered plant materials, extracts, tinctures, fatty or essential oils, expressed juices and preparations whose production involves fractionation, purification or concentration. The manufacturing procedure should be described in detail. If other substances are added during manufacture in order to adjust the plant preparation to a certain level of active or characteristic constituents or for any other purpose, the added substances should be mentioned in the manufacturing procedures. A method for identification and, where possible, assay of the plant preparation should be added. If identification of an active principle is not possible, it should be sufficient to identify a characteristic substance or mixture of substances (e.g. "chromatographic fingerprint") to ensure consistent quality of the preparation.
Finished product

The manufacturing procedure and formula, including the amount of excipients, should be described in detail. A finished product specification should be defined. A method of identification and, where possible, quantification of the plant material in the finished product should be defined. If the identification of an active principle is not possible, it should be sufficient to identify a characteristic substance or mixture of substances (e.g. “chromatographic fingerprint”) to ensure consistent quality of the product. The finished product should comply with general requirements for particular dosage forms.

For imported finished products, confirmation of the regulatory status in the country of origin should be required. The WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce should be applied.

Stability

The physical and chemical stability of the product in the container in which it is to be marketed should be tested under defined storage conditions and the shelf-life should be established.

Assessment of safety

This should cover all relevant aspects of the safety assessment of a medicinal product. A guiding principle should be that, if the product has been traditionally used without demonstrated harm, no specific restrictive regulatory action should be undertaken unless new evidence demands a revised risk-benefit assessment.

A review of the relevant literature should be provided with original articles or references to the original articles. If official monograph/review results exist, reference can be made to them. However, although long-term use without any evidence of risk may indicate that a medicine is harmless, it is not always certain how far one can rely solely on long-term usage to provide assurance of innocuity in the light of concern expressed in recent years over the long-term hazards of some herbal medicines.

Reported side-effects should be documented according to normal pharmacovigilance practices.

Toxicological studies

Toxicological studies, if available, should be part of the assessment. Literature should be indicated as above.

Documentation of safety based on experience

As a basic rule, documentation of a long period of use should be taken into consideration when assessing safety. This means that, when there are no detailed toxicological studies, documented experience of long-term
use without evidence of safety problems should form the basis of the risk assessment. However, even in cases of drugs used over a long period, chronic toxicological risks may have occurred but may not have been recognized. The period of use, the health disorders treated, the number of users and the countries with experience should be specified. If a toxicological risk is known, toxicity data must be submitted. The assessment of risk, whether independent of dose or related to dose, should be documented. In the latter case, the dosage specification must be an important part of the risk assessment. An explanation of the risks should be given, if possible. Potential for misuse, abuse or dependence must be documented. If long-term traditional use cannot be documented or there are doubts on safety, toxicity data should be submitted.

Assessment of efficacy

This should cover all important aspects of efficacy assessment. A review of the relevant literature should be carried out and copies provided of the original articles or proper references made to them. Research studies, if they exist, should be taken into account.

Activity

The pharmacological and clinical effects of the active ingredients and, if known, their constituents with therapeutic activity should be specified or described.

Evidence required to support indications

The indication(s) for the use of the medicine should be specified. In the case of traditional medicines, the requirements for proof of efficacy should depend on the kind of indication. For treatment of minor disorders and for non-specific indications, some relaxation in requirements for proof of efficacy may be justified, taking into account the extent of traditional use. The same considerations may apply to prophylactic use. Individual experiences recorded in reports from physicians, traditional health practitioners or treated patients should be taken into account.

Where traditional use has not been established, appropriate clinical evidence should be required.

Combination products

As many herbal remedies consist of a combination of several active ingredients, and as experience of the use of traditional remedies is often based on combination products, assessment should differentiate between old and new combination products. Identical requirements for the assessment of old and new combinations would result in inappropriate assessment of certain traditional medicines.
In the case of traditionally used combination products, the documentation of traditional use (such as classical texts of Ayurveda, traditional Chinese medicine, Unani, Siddha) and experience may serve as evidence of efficacy.

An explanation of a new combination of well known substances, including effective dose ranges and compatibility, should be required in addition to the documentation of traditional knowledge of each single ingredient. Each active ingredient must contribute to the efficacy of the medicine.

Clinical studies may be required to justify the efficacy of a new ingredient and its positive effect on the total combination.

**Intended use**

*Product information for the consumer*

Product labels and package inserts should be understandable to the consumer or patient. The package information should include all necessary information on the proper use of the product.

The following elements of information will usually suffice:

- name of the product
- quantitative list of active ingredient(s)
- dosage form
- indications
  - dosage (if appropriate, specified for children and the elderly)
  - mode of administration
  - duration of use
  - major adverse effects, if any
  - overdose information
  - contraindications, warnings, precautions and major drug interactions
  - use during pregnancy and lactation
- expiry date
- lot number
- holder of the marketing authorization.

Identification of the active ingredient(s) by the Latin botanical name, in addition to the common name in the language of preference of the national regulatory authority, is recommended.

Sometimes not all information that is ideally required may be available, so drug regulatory authorities should determine their minimal requirements.

*Promotion*

Advertisements and other promotional material directed to health personnel and the general public should be fully consistent with the approved package information.
Utilization of these guidelines

These guidelines for the assessment of herbal medicines are intended to facilitate the work of regulatory authorities, scientific bodies and industry in the development, assessment and registration of such products. The assessment should reflect the scientific knowledge gathered in that field. Such assessment could be the basis for future classification of herbal medicines in different parts of the world. Other types of traditional medicines in addition to herbal products may be assessed in a similar way.

The effective regulation and control of herbal medicines moving in international commerce also requires close liaison between national institutions that are able to keep under regular review all aspects of production and use of herbal medicines, as well as to conduct or sponsor evaluative studies of their efficacy, toxicity, safety, acceptability, cost and relative value compared with other drugs used in modern medicine.
Annex 12

Guidelines on import procedures for pharmaceutical products

1. Introductory notes

1.1 Public health considerations demand that pharmaceutical products should not be treated in the same way as ordinary commodities. Their manufacture and subsequent handling within the distribution chain, both nationally and internationally, must conform to prescribed standards and be rigorously controlled. These precautions serve to assure the quality of authentic products, and to prevent the infiltration of illicit products into the supply system.

1.2 Within the context of its revised drug strategy, adopted in 1986 by the Thirty-ninth World Health Assembly in resolution WHA39.27, WHO developed "Guiding principles for small national drug regulatory authorities" (1, 2) which established a regulatory approach in line with the resources available within a small national regulatory authority, and were intended to assure not only the quality, but also the safety and efficacy, of pharmaceutical products distributed under its aegis.

1.3 The principles emphasize the need for the effective use of the WHO Certification Scheme on the Quality of Pharmaceutical Products Moving in International Commerce. This constitutes a formal agreement between participating Member States to provide information on any product under consideration for export, notably on its registration status in the country of origin and whether or not the manufacturer complies with WHO's guidelines on good manufacturing practices (GMP) for pharmaceutical products (3).

1.4 To be fully effective, the Scheme needs to be complemented by administrative and other safeguards aimed at ensuring that consignments of imported products are in conformity in all particulars with the relevant import licence and that they remain secure within the distribution chain. Storage and transit facilities must be proof against tampering and adverse climatic conditions, and relevant controls must be applied at every stage of transportation.

1.5 Pharmaceutical products containing substances controlled under the international conventions have long been subjected to rigorous border controls. Some of these controls, and particularly those designed to prevent the diversion and illicit interchange of products during transit, are relevant to all pharmaceutical products, and are therefore included in these guidelines. Full details of the special import controls required for narcotic drugs and psychotropic substances are given in the Appendix.
2. **Objectives and scope**

2.1 The following guidelines, which stem from the above considerations, have been developed in consultation with national drug regulatory authorities, the pharmaceutical industry, the World Customs Organization, and the United Nations International Drug Control Programme.

2.2 The guidelines are directed to all parties involved in the importation of pharmaceutical products, including national drug regulatory authorities, competent trade ministries, customs authorities, port authorities, and importing agents.

2.3 They are intended to promote efficiency in applying relevant regulations, to simplify the checking and handling of consignments of pharmaceutical products in international transit and, *inter alia*, to provide a basis for collaboration between the various interested parties.

2.4 They are applicable to any pharmaceutical product destined for use within the country of import, and are intended to be adapted to prevailing national conditions and legal requirements.

3. **Legal responsibilities**

3.1 The importation of pharmaceutical products should be effected in conformity with regulations promulgated under the national drugs act or other relevant legislation and enforced by the national drug regulatory authority. National guidelines providing recommendations on the implementation of these regulations should be drawn up by the national drug regulatory authority in collaboration with the customs authority and other interested agencies and organizations.

3.2 All transactions relating to the importation of consignments of pharmaceutical products should be conducted either through the governmental drug procurement agency or through independent wholesale dealers specifically designated and licensed by the national drug regulatory authority for this purpose.

3.3 The importation of all consignments of pharmaceutical products should be channelled exclusively through customs posts specifically designated for this purpose.

3.4 All formalities undertaken on importation should be coordinated by the customs service, which should have the authority to request the services of an official pharmaceutical inspector as occasion demands. When justified by the workload, a pharmaceutical inspector may be stationed full time at one or more of the designated ports of entry.

3.5 The customs authority should have the discretionary powers to request technical advice and opinions from other appropriately qualified persons, should this be warranted by particular circumstances.
4. **Legal basis of control**

4.1 Subject to the exemptions specified in paragraph 4.4 below, only pharmaceutical products proved by appropriate documentation to be duly licensed for marketing within the importing country should be cleared by customs.

4.2 The national drug regulatory authority should compile comprehensive and frequently updated lists of licensed products and authorized importing agents, and issue notifications of any product licences withdrawn on grounds of safety; the latter should be rapidly communicated and presented in a manner designed to attract attention. All lists and notifications of withdrawal of a product licence should be accessible, preferably through a computerized database, to designated customs posts, authorized importing agents and all drug wholesalers.

4.3 Efficient and confidential channels for communicating information on counterfeit products and other illicit activities should be established between all interested official bodies.

4.4 In countries where no formal system of product licensing has been established, importation of products is most effectively controlled by issuing permits in the name of the national drug regulatory authority to the authorized importing agency or agent. Additional measures that may be taken under these conditions include:

- the provision by the national drug regulatory authority to the customs authorities, and to the importing agency and agents, of official lists of pharmaceutical products permitted and/or prohibited to be imported;
- the provision by the importing agent of certified information to establish that the product is authorized by licence for sale in the country of export.

4.5 The national drug regulatory authority should reserve discretionary powers to waive product licensing requirements in respect of consignments of pharmaceutical products imported in response to emergency situations and, exceptionally, in response to requests from clinicians for limited supplies of an unlicensed product needed for the treatment of a specific named patient.

5. **Required documentation**

5.1 As a prerequisite to customs clearance, the importing agency or agent should be required to furnish the customs authority with the following documentation in respect of each consignment:

- certified copies of documents issues by the national drug regulatory authority in the importing country, attesting that:
  (a) the importer is duly authorized by licence to undertake the transaction; and
  (b) the product is duly authorized by licence to be marketed in the importing country;
- a batch certificate issued by the manufacturer, consonant with the requirements of the WHO Certification Scheme, that documents the results of the final analytical control of the batch(es) constituting the consignment;
- a relevant invoice or bill and, when applicable, an authorization for the release of foreign exchange granted by the competent national authority in the country of import;
- any other documentation required by national legislation for customs clearance.

6. **Implementation of controls**

6.1 A visual and physical examination should be routinely undertaken by the customs authorities, if possible in collaboration with an inspector of the national drug regulatory authority. The size of the consignment should be checked against invoices, and particular attention should be accorded to the nature and condition of the packaging and labelling.

6.2 Arrangements should be made with the inspector of the national drug regulatory authority for the routine sampling and subsequent analysis of exceptionally large and/or valuable consignments and any other consignment that has apparently deteriorated, or that is damaged or of doubtful authenticity.

6.3 When samples are taken for analysis to a governmental or other accredited drug quality control laboratory, the consignment should be placed in quarantine. During this procedure, and throughout the time that the consignment is held in customs, particular care must be taken to ensure that packages do not come into contact with potential contaminants.

6.4 A consignment suspected of being counterfeit should be placed in quarantine pending the analysis of samples and forensic investigation. Time is often saved if materials and reagents needed to undertake simple analytical tests are available at the port of entry.

6.5 Representatives of the manufacturer of the authentic product, and/or the owner of the trademark, and the consignee should immediately be advised of such action.

6.6 National regulations should define the responsibilities of the interested parties and the precise procedures to be followed. In particular, the provisions should identify the agency responsible for coordinating the investigation and bringing prosecutions.

6.7 Counterfeit or other products which have been imported in contravention of the law must be forfeited and destroyed, or otherwise dealt with in accordance with legal procedures.

6.8 The relevant authorities must be indemnified against any consequent legal actions and proceedings.
6.9 National drug regulatory authorities are urged to notify other national authorities of confirmed cases of imported counterfeit pharmaceutical products through the Division of Drug Management and Policies of WHO.

7. **Procedures applicable to pharmaceutical starting materials**

7.1 In accordance with good manufacturing practices, formal responsibility for the analytical control of starting materials is vested in the manufacturer of the finished pharmaceutical product. Consequently, few countries have introduced formal licensing requirements for active pharmaceutical substances.

7.2 Exceptionally, however, some national authorities now exercise documentary and, in some cases, analytical control of starting materials as a prerequisite to customs clearance.

7.3 Each imported consignment of a pharmaceutical starting material should be accompanied by a warranty (or batch certificate) prepared by the manufacturer as recommended by the WHO Certification Scheme.

8. **Storage facilities**

8.1 Many pharmaceutical products tend to degrade on storage and some need to be kept in cold storage. All customs posts designated to handle consignments of pharmaceutical products should consequently be provided with secure storage facilities, including refrigerated compartments. If no pharmaceutical inspector is employed on site, these facilities should be inspected periodically by the national drug regulatory authority to ensure that all equipment is maintained in good working order.

8.2 The importing agency or agent should alert the customs authorities in advance of the anticipated arrival of consignments in order that they may be transferred from the international carrier to the designated storage facility with the minimum of delay and, in appropriate cases, without breaking the cold chain.

8.3. Consignments of pharmaceutical products and pharmaceutical starting materials should be accorded high priority for clearance through customs.

8.4 When several different consignments await clearance, the customs authorities should be guided by the drug inspector as to which should be accorded priority.

9. **Training requirements**

9.1 Performance in implementing the guidelines should be reviewed on an open-ended basis and, if necessary, improved in the light of on-site
monitoring and evaluation. Workshops designed to facilitate efficient implementation of the guidelines and to foster collaborative approaches between the various responsible parties should be organized, as circumstances demand, by the national drug regulatory authority in collaboration with the customs authority.

References


Glossary

The definitions given apply to the terms used in these guidelines. They may have different meanings in other contexts.

authorization
See Note.

counterfeit product
A pharmaceutical product that is deliberately and fraudulently mislabelled with respect to identity and/or source. Both branded and generic products can be counterfeited, and counterfeit products may include products with the correct ingredients, with the wrong ingredients, without active ingredients, with insufficient quantity of active ingredients or with fake packaging.

drug regulatory authority
The national agency responsible for the registration of, and other regulatory activities concerning, pharmaceutical products.

import authority
The national agency responsible for authorizing imports (e.g. the ministry or department of trade or of imports and exports).

importation
The act of bringing or causing any goods to be brought into a customs territory (national territory, excluding any free zone).
importer
An individual or company or similar legal entity importing or seeking to import a pharmaceutical product. A “licensed” or “registered” importer is one who has been granted a licence or registration status for the purpose. In addition to a general licence or permit as an importer, some countries require an additional licence to be issued by the national drug regulatory authority if pharmaceutical products are to be imported.

licence
See Note.

pharmaceutical product
Any medicine intended for human or veterinary use, presented in its finished dosage form, that is subject to control by pharmaceutical legislation in both the exporting state and the importing state.

registration
See Note.

starting material
Any substance of defined quality used in the production of a pharmaceutical product, but excluding packaging materials.

Note
Because of a lack of uniformity in national legal requirements and administrative practices, the terms “registered”, “licenced” and “authorized” have been used in these guidelines as if they were interchangeable. When the guidelines are being used as a basis for drawing up national guidelines, more precise terminology applicable to the country concerned should be used. In some countries, for example, “certificate of drug registration” has been replaced by terms such as “marketing authorization”. 
Appendix

Special import controls for narcotic drugs and psychotropic substances

In accordance with the requirements of the international drug control treaties (i.e. the Single Convention on Narcotic Drugs, 1961, and that Convention as amended by the 1972 Protocol, and the Convention on Psychotropic Substances, 1971, referred to subsequently as the 1961 Convention and the 1971 Convention), each state must adopt national legislation and administrative regulations, and establish administrative structures to ensure the full implementation of the provisions of these treaties on its territory and cooperation with other states.

Most of the requirements specified in these guidelines on import procedures for pharmaceutical products also apply to the border control of narcotic drugs and psychotropic substances. In addition, detailed information on the control of international trade in narcotic drugs and psychotropic substances can be found in Article 31 of the 1961 Convention and Article 12 of the 1971 Convention respectively. The guidelines provided in this Appendix are intended to facilitate the operation of control at entry points, and can be expanded by taking into account the legislation and administrative regulations in force in each country.

The customs authorities and, if applicable, any other law enforcement authorities assigned to border control should cooperate closely with the competent authorities for the control of narcotic drugs and psychotropic substances designated by the government (subsequently referred to as the competent authorities). It should be noted that, while the competent authorities in some countries are different from the national drug regulatory authority, in others they may be one and the same.

The customs authorities, or any other competent law enforcement authorities, should be well trained and equipped (e.g. with drug identification kits) so that they can distinguish consignments of narcotic drugs and psychotropic substances from other pharmaceutical products. They should be provided with lists of narcotic drugs and psychotropic substances under international control, e.g. the "Yellow List" and "Green List" published by the International Narcotics Control Board, which include, inter alia, trade names of pharmaceutical products containing narcotic drugs and psychotropic substances. They may also make use of the Multilingual dictionary of narcotic drugs and psychotropic substances under international control (ST/NAR/1/REV.1) published by the United Nations (sales number E/F/S.93.XI.2). Furthermore, they

should be provided with lists of narcotic drugs and psychotropic substances whose importation into the country has been prohibited.

Checks conducted during the border control of narcotic drugs and of psychotropic substances listed in Schedules I and II of the 1971 Convention should ensure that each consignment has been duly authorized by the competent authorities of the importing country. The competent authorities express their consent to each import by issuing an import certificate (for narcotic drugs) or an import authorization (for psychotropic substances). When presented with the original of this document, the competent authorities of the exporting country may issue an export authorization permitting the consignment containing narcotic drugs or psychotropic substances to leave the exporting country. In free ports and zones governments should exercise the same supervision and control as in other parts of their territory, provided, however, that they may apply more drastic measures if appropriate.

The competent authorities of the importing country may wish to inform the customs, or any other competent law enforcement authorities, of authorized imports of narcotic drugs and psychotropic substances before the entry of the consignment into the country.

In addition to the other documents referred to in section 5 of the guidelines, the customs authorities should require the importer or importer’s agent to provide them with a copy of the respective import authorization (certificate) issued by the competent authorities of the importing country. This document should be compared with the export authorization issued by the competent authorities of the exporting country, a copy of which must accompany each consignment. The authenticity of these documents must be carefully checked. In case of doubt, the competent authorities should be consulted immediately.

Import and export authorizations (certificates) should contain the following information:

- the name of the narcotic drug or psychotropic substance (if available, the International Nonproprietary Name);
- the quantity to be imported/exported, expressed in terms of anhydrous base content;
- the pharmaceutical form and, if in the form of a preparation, the name of the preparation;
- the name and address of the importer and exporter;
- the period of validity of the authorization.

In addition, the export authorization should contain the number and date of the corresponding import authorization/certificate and the name of the competent authority of the importing country by whom it was issued.

The competent authorities of the importing country may wish to specify in the import authorization/certificate the entry point through which the importation must be effected.
During the visual and physical examination of the imported consignment, the quantity of narcotic drugs or psychotropic substances contained in it should be carefully checked. If the quantity exceeds the amount authorized, the consignment should be stopped by the customs and the matter brought to the attention of the competent authorities for the control of narcotic drugs and psychotropic substances in the importing country. If the quantity imported is the same as, or less than, the amount authorized, the quantity should be recorded on the copy of the export authorization accompanying the consignment and communicated to the competent authorities of the importing country.

All consignments containing psychotropic substances included in Schedule III of the 1971 Convention must be accompanied by a separate export declaration. This document should indicate the name and address of the exporter and importer, the name of the substance, the quantity and the pharmaceutical form in which the substance is exported, including, if applicable, the name of the preparation and the date of dispatch.

Pursuant to the recommendations contained in resolutions of the Economic and Social Council of the United Nations, many governments now require import authorizations not only for psychotropic substances in Schedules I and II but also for those in Schedules III and IV of the 1971 Convention. This strengthening of the control requirements has proved to be very useful in preventing attempts to divert psychotropic substances, such as stimulants, sedative-hypnotics and tranquillizers, into illicit traffic.